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“There is no such thing as a disembodied mind. The mind is implanted in the brain, and 
the brain is implanted in the body”. Antonio Damasio 
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1. INTRODUCTION  
Way back in 1845, Heinrich Hoffmann described in his book Struwwelpeter typical 
ADHD-like behavior which is known colloquially in Germany as the Zappel-Philipp syndrome. 
However, it took until 1968 that this was first introduced in the DSM-II as hyperkinetic reaction 
of childhood, until 1978 in ICD-9 as Hyperkinetic disorder and in 1980 it was introduced in the 
DSM-III as Attention Deficit Disorder. Nowadays, it is known as Attention-deficit/Hyperactivity 
and Impulsivity disorder (ADHD), and from a societal point of view, ADHD has a high financial 
impact on the health care system. A 2013 survey in Europe estimated costs related to ADHD be-
tween 9.860 and 14.483 Euros per patient/year (Le et al., 2014). Although common 
pharmacological treatment strategies provide short-term benefit with good clinical results there 
are important constraints which should be further investigated (for details see: Cortese, 2018). 
Additionally, this disorder is characterized by its large comorbidity rate with aggression-related 
disorders which may limit the efficacy of ADHD treatments and contributes substantially to the 
global burden of disease. This thesis aims at evaluating new non-pharmacological treatment mo-
dalities, such as neurofeedback training for core ADHD symptoms and for aggression-related 
behavior. In the following sections, we will summarize insights about these externalizing disor-
ders, their neurobiological underpinnings, and possible new efficacious non-pharmacological 
treatment strategies.  
1.1 Externalizing disorders 
Externalizing disorders are commonly referred to as disruptive behavior disorders (DBD). 
These disorders are the most prominent psychiatric referrals during childhood and adolescence 
and consist of ADHD, oppositional defiant disorder (ODD) and conduct disorder (CD). In the 
next section, we will provide a concise description of their underlying psychopathology. 
1.1.1 Attention-Deficit/Hyperactivity Disorder (ADHD) 
ADHD is defined as a developmental disorder, and the core symptoms comprise hyperac-
tivity, impulsivity, and inattention. According to the classification system DSM-5 (American 
Psychiatric Association, 2013), functional impairment needs to be present for more than 6 
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months, in more than one environment (e.g. home and school), and six or more symptoms need to 
be present before the age of 12 years. Symptoms of inattention are described as failing to give 
closer attention to details, being negligent in schoolwork, or during other activities, showing dif-
ficulties sustaining attention in different tasks or play activities and encompass difficulties in or-
ganizational skills. Regarding the dimensions of hyperactivity and impulsivity, these symptoms 
involve excessive energy and acting as if “driven by a motor” (i.e. runs or climbs in inappropriate 
situations) or interrupting conversations. The latest classification system (DSM-5), distinguishes 
presentations and severity of the core symptoms instead of subtypes within this disorder. It in-
cludes a combined, a predominantly inattentive, or a hyperactive/impulsive presentation, and 
mild, moderate or severe forms.  
1.1.1.1 Prevalence 
With regard to the prevalence rate, ADHD is the most frequent externalizing disorder in 
childhood and adolescence with a worldwide prevalence of 2.6-4.5% (Polanczyk, Salum, Sugaya, 
Caye, & Rohde, 2015), and affecting more boys than girls (ratio 3:1; Wittchen et al., 2011). Fur-
ther, it is considered a heterogeneous disorder, with high comorbidity up to 75% with ODD/CD, 
learning disorders, and autism spectrum disorder (Jensen & Steinhausen, 2015). 
1.1.1.2 Etiology 
ADHD is considered a highly heritable disorder, with 70% to 80% of variance associated 
with genetic factors. Dysfunctions in dopaminergic, noradrenergic and serotonergic neurotrans-
mitter systems were linked to ADHD (Banaschewski, Becker, Scherag, Franke, & Coghill, 2010; 
Faraone et al., 2005). Nevertheless, psychosocial factors (i.e. familial context and parenting) may 
serve as moderators of genetic influences (Nigg, Nikolas, & Burt, 2010; Nikolas, Klump, & Burt, 
2015). Additionally, pre- and perinatal environmental factors have been related to ADHD. In 
particular low birth weight (Franz et al., 2018), smoking during pregnancy (Holz et al., 2014), 
low income and prematurity, but these findings are correlative in nature due to the lack of exper-
imental studies (for details see: Thapar, Cooper, Eyre, & Langley, 2013). In general, it is likely 
that due to the complexity of the disorder multiple factors may cause the pathophysiology, possi-
bly resulting in a heterogeneous group of patients (Thapar et al., 2013). 
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1.1.1.3 Neurobiology and neurophysiology 
Recent brain imaging findings showed an association between ADHD and reduced sub-
cortical brain volume (Hoogman et al., 2017). This cross-sectional mega-analysis comprised a 
sample of 1713 participants with ADHD and 1529 controls. Hoogman and colleagues showed 
reduced volumes of the accumbens, amygdala, caudate, hippocampus, putamen and intracranial 
volume in the ADHD population with small, but robust effect sizes. Earlier studies found reduced 
gray matter volume in frontal and temporal regions, as well as in the caudate and the cerebellum 
(Castellanos et al., 2002; Frodl & Skokauskas, 2012), highlighting that disease etiology cannot be 
attributed to single dysfunctional brain regions. In accordance with this,  a meta-analysis on func-
tional brain imaging studies (Cortese et al., 2012) highlighted significant distributed deficits in 
the frontoparietal executive/ventral inhibition-related attention network but also emphasized in-
creased recruitment of the somatomotor system and the putamen, with the latter possibly explain-
ing the observed motor hyperactivity. In addition to the well-known deficient frontostriatal acti-
vation, increased activation in other default and visual areas has also been demonstrated, which is 
in line with the fluctuating attentional focus during cognitive performance in ADHD (Baroni & 
Castellanos, 2015; Cortese et al., 2012). Interestingly, the structural findings are in line with the 
brain regions previously identified as being compromised in their function (Cortese et al., 2012). 
Electrophysiology findings in ADHD showed that slower oscillations, such as theta, al-
pha, but as well faster beta frequencies bands to be the most relevant in ADHD research (Loo & 
Makeig, 2012). A frequent and highly controversial finding is a higher proportion of a frontocen-
tral theta/beta ratio (Snyder, Rugino, Hornig, & Stein, 2015). These authors argue that this elec-
trophysiological parameter can be used as a biomarker which might be useful as a diagnostic aid 
for ADHD. Nevertheless, this remains controversial, and an additional review concluded that 
theta/beta ratio as a diagnostic aid for ADHD is unclear in its definitions and does not integrate a 
good clinical practice of ADHD diagnosis (Loo & Arns, 2015). However, this might be explained 
by the heterogeneity within ADHD, since a particular subgroup shows larger theta/beta ratio 
(Clarke et al., 2011). Besides this controversial outcome regarding the electrophysiological spec-
trum, there are interesting findings concerning event-related potentials (ERPs). Different ERP 
components showed deviations in ADHD for stimulus discrimination, resource allocation, 
inhibition, preparation, error detection and conflict processing (Barry, Clarke, & Johnstone, 2003; 
Barry et al., 2003; Johnstone, Barry, & Clarke, 2013). However, these alterations seem to be non-
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specific to ADHD and provide only limited relevance as diagnostic biomarkers (Loo & Makeig, 
2012). Nevertheless, a current meta-analysis (Kaiser et al., in prep), found significant and moder-
ate to large effects for specific ERPs associated with attentional preparation and resource alloca-
tion.  
1.1.2 Oppositional defiant disorder (ODD) and Conduct disorder (CD) 
According to the DSM-5 (American Psychiatric Association, 2013), Oppositional defiant 
disorder (ODD) is characterized by disruptive and impulsive behavior, and conduct problems. 
Furthermore, essential characteristics of ODD are disobedience, defiance and a negative attitude 
towards authorities. The persistence and frequency of these behaviors is a crucial factor and 
should be used to distinguish whether the individual’s behavior falls outside the median for the 
individual’s developmental level. A persistent pattern of angry, irritable mood, defiant behavior 
and vindictiveness should last at least 6 months to meet this diagnostic criterion. The symptoms 
of ODD can be present only in one setting, and this is frequently the own home. Children and 
adolescents who show enough symptoms to meet the diagnostic criteria, even only in one setting, 
may be significantly impaired in their social functioning.  
Conduct disorder (CD) is defined as a repetitive and persistent pattern of behavior which 
violates the rights of others and major age-appropriate societal rules (American Psychiatric Asso-
ciation, 2013). To reach clinical relevance, three out of 15 symptoms have to be met. Symptoms 
are characterized predominantly by bullying, intimidation, physical fights, cruelty to people or 
animals, vandalism and serious violations of rules. Aggression-related behavior, mostly present’s 
two different subtypes of externalizing behavior. Recently, the concept of callous-unemotional 
(CU) traits, possibly implied in instrumental aggression (Frick & Ellis, 1999), has attracted in-
creasing interest (Buitelaar et al., 2013; Viding & McCrory, 2012). In line with this, DSM-5 
(American Psychiatric Association, 2013) added a new prosocial specifier, which pertains to pa-
tients suffering from the more severe CU behavior. CU traits comprise lack of remorse or guilt, 
lack of empathy, indifference about performance, and shallow or deficient affect. Additionally, 
two different phenotype distinctions (reactive and proactive aggression) are often made to sub-
type aggressive behavior (Raine et al., 2006). Reactive aggression is associated with impulsive, 
high arousal, hot-blooded or affective aggression whereas proactive aggression refers to goal-
directed, planned behavior associated with reduced arousal and higher levels of callous-
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unemotional traits, also known as instrumental or cold-blooded aggression (Blair, Peschardt, 
Budhani, Mitchell, & Pine, 2006).  
 In section 1.2.4 we will further discuss the heterogeneity of distinct phenotypic behavior 
of aggression.  
1.1.2.1 Prevalence 
ODD is a developmental disorder with a similar worldwide prevalence as ADHD, which 
ranges between 2.8-4.7% (Polanczyk et al., 2015). Further, it is more prevalent in males than in 
females (ratio 1.4:1) prior to the adolescence, however, this predominance is not consistently 
found in samples of adolescents or adults (American Psychiatric Association, 2013). Regarding 
comorbidity, ODD shows a high overlap with ADHD, which ranges between 35% to 50% (Con-
nor, Steeber, & McBurnett, 2010) and could be associated with shared temperamental risk factors 
(American Psychiatric Association, 2013). Further, there is also an increased risk of comorbid 
anxiety disorders and mood disorders. Adolescents with ODD also show a higher rate of sub-
stance use disorder and conduct disorder (American Psychiatric Association, 2013). With regard 
to CD, the prevalence rate is lower at about 2% (2.5% in males, 1.5% in females; Rowe et al., 
2010) with a median age at onset of 12 years (Nock et al., 2006).  
1.1.2.2 Etiology 
In general, within these disorders, the etiology is less clear than in ADHD. Overall, nu-
merous factors, including familial, genetic, biological, individual and environmental factors have 
been identified that may play a role in the etiology of aggression-related behavior (Chris-
tophersen & Finney, 1999). Poverty is a well-known risk factor (Costello, Compton, Keeler, & 
Angold, 2003; Holz et al., 2015; Piotrowska, Stride, Croft, & Rowe, 2015). Almost 60% of fami-
lies of children with behavioral problems showed lower SES (Alvarez & Ollendick, 2003; Loe-
ber, Green, Keenan, & Lahey, 1995). Regarding genetic factors, Slutske and colleagues (2003) 
estimated that approximately 13 percent of the variation in the risk for aggression-related behav-
ior symptoms could be explained by non-shared individual-specific environmental factors and 
heritability of 50% (Gelhorn et al., 2005). Further, it has often been said that the best predictor of 
future behavior is past behavior, and this may be the case with aggression-related behavior as 
well (Crowell et al., 2006). In fact, if behavior problems are stable from preschool to school age, 
Introduction 
 
15 
they are more likely to continue into adolescence (Ewing & Campbell, 1995) and, probably, 
adulthood (Moffitt, 1993). Overall, the link between early aggression and later development of 
behavioral problems has been well established (Alvarez & Ollendick, 2003; Sanson & Prior, 
1999). 
1.1.2.3 Neurobiology and neurophysiology 
As for ADHD, several studies have focused on structural abnormalities in aggression-
related behavior. A recent meta-analysis of thirteen studies analyzed almost 400 participants 
(aged 9-21 years) with conduct problems showed reduced grey matter volumes in the left amyg-
dala, in the bilateral insula extending to the ventrolateral prefrontal cortex (PFC)/orbitofrontal 
cortex (OFC) and in the medial superior frontal gyrus extending to the anterior cingulate cortex 
(ACC) with small to medium effect sizes (Rogers & De Brito, 2016). An additional meta-analysis 
including ODD/CD and ADHD studies (n=415, age 8-21 years) reported reduced volumes of the 
amygdala, insula, and frontal regions in participants diagnosed with ODD/CD as well, and with 
greater reductions in the presence of comorbid ADHD (Noordermeer, Luman, & Oosterlaan, 
2016). With regard to functional MRI findings, current neuroimaging studies of aggression-
related disorders are in line with the neuropsychological literature implicating deficits in both 
affective and executive function as well as reward processing (Blair et al., 2006; Nigg & Huang-
Pollock, 2003). Specifically, children with ODD/CD show impaired amygdala activity in re-
sponse to negative face stimuli, suggesting impaired recognition of facial expression (Blair, 
Leibenluft, & Pine, 2014). However, there are mixed outcomes and subtype-specific differences 
should be taken into account since evidence for hypo and hyperactivity were found, which are 
probably moderated by CU traits (Viding, Seara-Cardoso, & McCrory, 2014). The third study of 
this thesis will specifically investigate this underlying neural heterogeneity within aggression-
related subtypes. 
With regard to electrophysiological findings, there are very little studies that have investi-
gated electrophysiological deviations in patients with aggression. These studies have found strik-
ing similarities to ADHD patients. As such, higher slow-wave activity, such as more theta activi-
ty which is normally associated with ADHD, was found in studies of delinquent children 
(Knyazev, Slobodskaya, Aftanas, & Savina, 2002), in antisocial personality disorder (Lindberg et 
al., 2005) and teenagers who later committed crimes in adulthood (Raine, Venables, & Williams, 
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1990). Furthermore, typically decreased beta waves in ADHD has been also found in antisocial 
participants (Gilmore, Malone, & Iacono, 2010). Taking together the findings for both disorders, 
there appears to be a link with ADHD and other forms of externalizing disorders. However, in 
both cases, inconsistent results have been reported. For example, Clarke and colleagues speculat-
ed that higher levels of beta activity may define a particular subgroup of children with ADHD, 
which might be more hyper-aroused and possibly more hyperactive than other children with 
ADHD (Clarke, Barry, McCarthy, & Selikowitz, 2001). Interestingly, similar results were report-
ed in a sample of homicidal men (Lindberg et al., 2005).  
A recent meta-analysis of 62 studies tried to disentangle the literature of ADHD and ag-
gression-related disorders. Externalizing behaviors compared to ADHD showed a negative rela-
tionship between alpha power and antisocial behavior and that exclusive slow-waves were 
particularly sensitive for ADHD, but not for antisocial or mixed samples (Rudo-Hutt, 2015). 
Nevertheless, there seems to be a large overlap between ADHD and other externalizing disorders, 
which is not surprising, since there exists a large overlap regarding the clinical phenotype. Addi-
tionally, it is worth noting that there is a lack of studies that investigate aggression-related disor-
ders with EEG and in relation to ADHD.   
1.2 Treatments in ADHD  
The German guidelines for ADHD published in 2018, recommend a multimodal treat-
ment, which includes the following components: parent-oriented counseling, psychoeducation, 
cognitive-behavioral therapy, and pharmacological treatment. Neurofeedback and dietary re-
strictions are mentioned as possibly helpful interventions. Neurofeedback applying standard 
training protocols can be added as a complementary option treating ADHD symptoms, and if they 
do not interfere with other efficacious treatment. While other guidelines (i.e. NICE) do not ad-
dress neurofeedback in their ADHD guidelines. 
1.2.1 Pharmacological treatment 
In severe ADHD patients and older than 5 years, the first-line treatment is pharmacologi-
cal. Stimulants, such as Methylphenidate (MPH) are the most common and effective used drug to 
treat the core symptoms of ADHD. The effect sizes are large and ranges between 0.7 and 1 
(Banaschewski et al., 2006; Cortese, 2018) and about 70% of patients respond to stimulant treat-
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ment (Spence et al., 1996). In particular, stimulants act over the catecholamine neurotransmitters, 
increasing i.e. dopamine and noradrenaline. Besides the high effect in reducing symptoms, there 
are important constraints worth mentioning. Adverse events (Graham et al., 2011), unwillingness 
to take the medication over extended periods (Berger, Dor, Nevo, & Goldzweig, 2008), and the 
absence of long-term effects (van de Loo-Neus, Rommelse, & Buitelaar, 2011) are important 
factors which needs to be taken into account when administering pharmacotherapy.  
1.2.2 Non-pharmacological treatment 
A recent network meta-analysis (Catalá-López et al., 2017) which analyzed 26114 ADHD 
patients in 190 randomized controlled trials found that behavioral therapy in combination with 
pharmacological treatment is superior to pharmacological interventions alone, and behavioral 
therapy particularly with parent and teacher involvement, was the only non-pharmacological in-
tervention associated with significant benefits for ADHD patients. Other non-pharmacological 
approaches, such as dietary therapy, cognitive training, physical activity, and neurofeedback, 
could not be recommended. Nevertheless, they concluded that “there are uncertainties about 
therapies and the balance between benefits, costs and potential harms, which should be consid-
ered before starting treatment and that there is an urgent need for high-quality RCTs”. An earlier 
meta-analysis focusing only on non-pharmacological ADHD treatments showed that cognitive 
training and behavioral interventions had a significant impact on ADHD symptoms reduction 
with medium to large effect sizes when parents rated the behaviors (Sonuga-Barke et al., 2013). 
Additionally, no significant ADHD symptom reduction was found when probably blind raters 
evaluated ADHD behavior, however, significant effect emerged for conduct problems (Daley et 
al., 2014; Sonuga-Barke et al., 2013). 
In summary, non-pharmacological treatments are an important part of the multimodal 
treatment of children with ADHD, however, more research is required to understand how to op-
timize treatment response (Daley et al., 2017). 
1.2.3 Neurofeedback and biofeedback treatment 
Neuro- and biofeedback approaches are techniques in which a variety of unconscious psy-
chophysiological signals (i.e. brain waves, ERPs, skin conductance or bold signal) are feed-
backed to the patient (Figure 1). The regulation of psychophysiological signals is trained based 
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on operant conditioning (Sherlin et al., 2011). One of the first studies which demonstrated learn-
ing and modulation of unconscious psychophysiological signals was in Cats. Wyrwicka, Sterman, 
& Clemente (1962) conditioned successfully the sensorimotor rhythm (SMR;12-15Hz). Addi-
tionally, Neal E. Miller (1969) promoted the term of Biofeedback with the visceral learning theo-
ry. So far, there exist a considerable number of studies showing successful regulation and learn-
ing of brain- and body- related activity mainly in healthy adult humans (for review see Frank, 
Khorshid, Kiffer, Moravec, & McKee, 2010; Thibault, Lifshitz, Birbaumer, & Raz, 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
With regard to the effectiveness of neurofeedback in reducing ADHD symptoms, there is 
a comparable large amount of meta-analyses available (Arns, de Ridder, Strehl, Breteler, & 
Coenen, 2009; Cortese et al., 2016; Doren et al., 2018; Micoulaud-Franchi et al., 2014; Riesco-
Matías, Yela-Bernabé, Crego, & Sánchez-Zaballos, 2019; Sonuga-Barke et al., 2013). A very 
recent published meta-analysis tried to sum up these findings (Riesco-Matías et al., 2019). The 
Figure 1. Conceptual diagram of Neuro/Biofeedback. fMRI: functional magnetic reso-
nance imaging; EEG: Electroencephalogram, SCR: Skin conductance response. 
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authors reviewed seven meta-analyses which incorporated 17 RCTs. A significant effect was 
found for the ADHD core symptoms rated by parents and for inattention subdomain when proba-
bly blinded raters (teachers) assessed the symptoms. The effect sizes varied between small and 
medium for parent ratings and were small for teacher ratings. These significant effects in favor of 
neurofeedback held only when it was compared to non-active control groups, while pharma-
cotherapy (active condition) showed to be significantly superior to neurofeedback with large to 
medium effect sizes.  
However, sustained and long-term clinical effects still remain less systematically studied. 
Only one meta-analysis from Van Dooren and colleagues (2018), on ten studies, showed small to 
medium effects in favor of neurofeedback when compared to non-active and comparable results 
as active conditions six months after treatment. So far, there are a few studies which showed in-
teresting long lasting effects which probably might be related to delayed learning effects after 
neurofeedback. Specifically, Strehl et al., (2006) showed enhanced performance in a specific neu-
rofeedback condition (transfer) which was related to clinical improvement. The transfer condition 
aims to extrapolate the learned skills into daily live situation. Interestingly, in epilepsy patients, a 
similar delayed effect was found (Kotchoubey et al., 1999).  This might be a promising hint for 
long-lasting effects after neurofeedback. However, studies assessing longer-term effects are still 
underrepresented and of particular clinical importance. Therefore, part of this thesis will assess 
these longer-term effects of neurofeedback treatment on ADHD symptoms, as well as on comor-
bid aggression disorders. 
Furthermore, it is worth mentioning that neurofeedback and biofeedback are umbrella 
terms. There are a large number of different training protocols which are only limited by the 
available technology. In the case of EEG neurofeedback, there are many different ways to train 
and modulate brain-associated patterns (i.e. SMR, Theta/Beta, SCP-NF, Coherence, and asym-
metry feedback). Consequently, a recent meta-analysis (Cortese et al., 2016) and the German 
ADHD guidelines (AWMF, 2018: ADHS bei Kindern, Jugendlichen und Erwachsenen, Register-
nummer 028 – 045) recommended only three training procedures for ADHD (SMR, Theta/Beta 
and SCP Neurofeedback). Therefore, this thesis is only based on these ‘standard’ training proto-
cols.  
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1.2.4 Aggression-related symptoms in ADHD 
In general, aggression-related problems in ADHD are treated with modest cost-benefits 
effects. Stimulant (i.e. MPH), and neuroleptic (i.e. risperidone) treatments showed significant 
effects on comorbid aggression in ADHD patients. Nevertheless,  pharmacotherapy of aggression 
is limited by quality, the existing literature and serious adverse effects (Pappadopulos et al., 
2006), therefore first-line treatment should be psychosocial interventions, which are supported by 
substantial evidence and have low risks for adverse effects (Wilkes & Nixon, 2015).  
With regard to neurofeedback effects on comorbid aggression, only a few studies are 
available. Gevensleben and colleagues (2009) showed significant reductions in parent-rated op-
positional behavior compared to standardized computerized attention training. Additionally, after 
theta/beta NF training, reduction of ODD symptoms was reported but without group difference 
compared to standard pharmacological intervention (Meisel, Servera, Garcia-Banda, Cardo, & 
Moreno, 2013). Furthermore, one study investigated SCP-NF in criminal psychopaths showing 
less aggression and impulsivity (Konicar et al., 2015). Since there is little literature available, part 
of this thesis will address the effects of neurofeedback on aggression-related symptoms. The po-
tential psychophysiological targets which could be modulated in aggression-related behavior are 
still unclear. Some less widely available NF treatments, such as real-time NF, showed that up-
regulation of the anterior insula had a significant impact on aggression (Sitaram et al., 2014). 
Nevertheless, there is a gap which tries to address the heterogeneity of aggression-related disor-
ders. In this thesis, we will analyze if the different aggression-related subtypes provide more in-
sight into the underlying neurobiology which might be used for new NF-approaches.  
1.3 Hypotheses 
The clinical relevance of NF treatment has been supported by previous literature, as re-
viewed in section 1.2.3. However, evidence so far has been sparse with regard to NF specificity, 
clinical long-term effects, as well as its relationship with self-regulation and the influence on 
comorbid aggression.  
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1.3.1 Specific vs unspecific effects of SCP-NF 
Two main approaches can disentangle specific from unspecific effects. First, the compari-
son with effects of a good control condition, and second the relationship between self-regulation 
of the trained parameters and clinical improvement (Drechsler et al., 2007; Ros, 2019). With re-
gard to the control condition, this RCT assessed the differential treatment effects between both 
treatment conditions, while controlling for unspecific effect. We hypothesize that SCP-NF will 
show superiority in comparison to the control group, and that self-regulation is associated with 
clinical outcome (Study 1). 
1.3.2 Long-term effects 
Regarding long-term clinical outcome, in line with the already discussed meta-analysis (    
Doren et al., 2018), we expect clinical superiority six-month after SCP-NF treatment compared to 
the control condition (Study 2). 
1.3.3 Influence on comorbid aggression  
As already discussed in section 1.2.4, there are only a few studies which investigated the 
effect of NF approaches on aggression with promising results. Thus, we hypothesize that SCP-NF 
will reduce aggression-related problems (Study 1 & 2). 
1.3.4 Putative Neurofeedback targets for aggression-related disorders 
To optimize treatment effects for aggression-related disorders we need to disentangle the 
heterogeneity of these disorders. Distinct subtypes of aggression, and as well CU traits might 
show divergent and phenotype-specific neural activity. Therefore, in study 3 we hypothesize that 
patients with more proactive aggression will show blunted activation of core limbic structures, 
such as the amygdala (Study 3). 
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2. EMPIRICAL STUDIES 
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2.1 Study 1: Neurofeedback of Slow Cortical Potentials in Children with Attention-
Deﬁcit/Hyperactivity Disorder: A Multicenter Randomized Trial Controlling for 
Unspeciﬁc Effects 
 
 
 
 
 
_______________________ 
Published as: Strehl, U., Aggensteiner, P., Wachtlin, D., Brandeis, D., Albrecht, B., Bach, C., … 
Holtmann, M. (2017). Neurofeedback of Slow Cortical Potentials in children with Atten-
tion-Deficit/Hyperactivity Disorder (ADHD): a multicenter randomized trial controlling 
for unspecific effects. Frontiers in Human Neuroscience, 11. 
https://doi.org/10.3389/fnhum.2017.00135 
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2.1.1 Abstract 
 Neurofeedback (NF) in children with attention-deﬁcit/hyperactivity disorder (ADHD) has 
been investigated in a series of studies over the last years. Previous studies did not unanimously 
support NF as a treatment in ADHD. Most studies did not control for unspeciﬁc treatment effects 
and did not demonstrate that self-regulation took place. The present study examined the efﬁcacy 
of NF in comparison to electromyographic (EMG) feedback to control for unspeciﬁc effects of 
the treatment, and assessed self-regulation of slow cortical potentials (SCPs).  
A total of 150 children aged 7–9 years diagnosed with ADHD (82% male; 43% medicat-
ed) were randomized to 25 sessions of feedback of SCPs (NF) or feedback of coordination of the 
supraspinatus muscles (EMG). The primary endpoint was the change in parents’ ratings of 
ADHD core symptoms 4 weeks after the end of treatment compared to pre-tests.  
Children in both groups showed reduced ADHD-core symptoms (NF 0.3, 95% CI −0.42 
to −0.18; EMG 0.13, 95% CI −0.26 to −0.01). NF showed a signiﬁcant superiority over EMG 
(treatment difference 0.17, 95% CI 0.02–0.3, p = 0.02). This yielded an effect size (ES) of d = 
0.57 without and 0.40 with baseline observation carried forward (BOCF). The sensitivity analysis 
conﬁrmed the primary result. Successful self-regulation of brain activity was observed only in 
NF. As a secondary result teachers reported no superior improvement from NF compared to 
EMG, but within-group analysis revealed effects of NF on the global ADHD score, inattention, 
and impulsivity. In contrast, EMG feedback did not result in changes despite more pronounced 
self-regulation learning. 
 Based on the primary parent-rated outcome NF proved to be superior to a semi-active 
EMG feedback treatment. The study supports the feasibility and efﬁcacy of NF in a large sample 
of children with ADHD, based on both speciﬁc and unspeciﬁc effects. 
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2.1.2 Introduction 
Attention-deﬁcit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder in 
childhood. According to DSM-IV TR (in eﬀect during this trial), core symptoms include im-
paired attention, hyperactivity, and impulsivity (American Psychiatric Association, 2000). Stimu-
lant medication represents the most commonly used intervention for children with ADHD, but its 
use is limited since in some children pharmacotherapy may fail, adverse side eﬀects are common, 
long-term eﬀects are not yet established and some parents and clinicians have reservations about 
medication use (Sonuga-Barke et al., 2013). 
Among additional or alternative treatments for ADHD neurofeedback (NF) has gained 
promising empirical support in recent years. Based on the observation of deviant slow event-
related potentials in children with ADHD, feedback of slow cortical potentials (SCPs-NF) aims at 
improving the neurophysiological proﬁle of children with ADHD by self-regulation of cortical 
excitation thresholds (Albrecht et al., 2010; Banaschewski & Brandeis, 2007; Doehnert, Brande-
is, Schneider, Drechsler, & Steinhausen, 2013) SCPs are slow event-related changes in the EEG, 
reﬂecting cognitive and motor preparation (Birbaumer, Elbert, Canavan, & Rockstroh, 1990). 
Studies have demonstrated promising eﬀects on behavior, cognitive, and electrophysiological 
measures after SCP-NF (Christiansen, Reh, Schmidt, & Rief, 2014; Drechsler et al., 2007; Ge-
vensleben et al., 2009; Heinrich, Gevensleben, Freisleder, Moll, & Rothenberger, 2004; Maurizio 
et al., 2013; Strehl et al., 2006). A recent meta-analysis failed to support NF as an eﬀective treat-
ment for ADHD but this result may reﬂect methodological weaknesses of the available studies 
rather than the weakness of NF as such (Cortese et al., 2016). When the analysis was restricted to 
trials meeting Arns et al.’s (2013) criteria for a standard (established) NF protocol (as related to 
the target EEG measures, to number and placement of electrodes, trials designed in line with 
principles of learning theory, involving techniques to promote generalization to everyday life and 
assessing whether learning took place), signiﬁcant eﬀects emerged also applying probably blind-
ed ratings. The main drawbacks of previous SCP studies are methodological shortcomings like 
lack of appropriate control conditions, intent-to-treat analyses, unblinded outcome measures, lim-
ited testing for successful self-regulation at the brain level, and failure to control unspeciﬁc 
eﬀects and variables (e.g., amount of reinforcement, time, attention of and interaction with the 
therapist; sex, age, baseline severity, expectations, and satisfaction with treatment). To disentan-
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gle NF-speciﬁc and unspeciﬁc eﬀects inﬂuencing the outcome of any treatment the choice of a 
control condition is of major importance (Oken, 2008). Active control conditions do not control 
for unspeciﬁc eﬀects as the independent variables causing them diﬀer as regards, e.g., to setting, 
expectation, interaction, time, and eﬀort. For example, medication cannot control for the un-
speciﬁc eﬀects of time and attention spent concentrating on the challenging self-regulation task, 
and for the experience of learning with contingent feedback. Double-blind studies which employ 
a sham condition may provide strong unbiased evidence regarding eﬃcacy and speciﬁcity, and 
thus have clear merits in NF research (Kerson & Collaborative Neurofeedback Group, 2013) 
which may involve considerable non-speciﬁc eﬀects (Drechsler et al., 2007; Thibault and Raz, 
2016). While double-blind controlled placebo studies in general may provide strong evidence 
regarding eﬃcacy and speciﬁcity, the establishment of sham conditions for NF treatments has 
shown to be at least doubtful if not missing the main aim. Patients and trainer can detect the sham 
condition and may refuse further participation (Birbaumer et al., 1991). Another outcome was 
observed by van Dongen-Boomsma et al., (2013). Here the majority of patients in the NF condi-
tion assumed that they were assigned to the sham condition. As any acquisition of a new skill, 
learning to self-regulate brain activity takes time. The lack of success in the ﬁrst sessions may 
lead to the impression of being allocated to an ineﬀective control condition. As a consequence, 
this may impair motivation and compliance. However, apart from potential ethical and expectan-
cy motivation problems of sham designs, an ideal control condition for NF should also require 
learning to fully match moderator variables such as motivation, frustration, compliance, and the 
often stepwise experience of self-eﬃcacy (Gevensleben et al., 2014). Recent neuroimaging re-
search demonstrates speciﬁc increases of activity in brain regions supporting inhibitory control 
following learning of diﬀerent types of self-regulation in ADHD (Baumeister et al., 2016). There-
fore, sham conditions that do not allow learning genuine contingencies also have limitations 
(Sherlin et al., 2011; Arns et al., 2014). To induce learning of self-regulation but limited to pe-
ripheral rather than central nervous targets, we chose a semi-active control condition according to 
the classiﬁcation put forward by Arns et al., (2014) in comparing NF with electromyographic 
(EMG) feedback. Despite not being closely related to the known pathology of ADHD, EMG 
feedback has been used in several ADHD treatment studies and as a control condition for NF. 
Some improvements but smaller than those from NF were reported  (Arnold, 2001; Bakhshayesh, 
Hänsch, Wyschkon, Rezai, & Esser, 2011; Maurizio et al., 2013). Thus, even participants in the 
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control condition have the chance to reduce symptoms and learn self-regulation, but not based on 
a treatment speciﬁc to the pathology of the disease. Delivering identical treatment elements in 
both conditions apart from the speciﬁc (NF or EMG) component should allow diﬀerentiating 
speciﬁc from unspeciﬁc eﬀects of NF. The aim of this investigation was to assess the eﬀective-
ness, speciﬁcity and feasibility of SCP-NF in comparison to EMG feedback in a prospective, ran-
domized and controlled study, while neurophysiological data and more detailed learning analyses 
and correlations with clinical outcomes will be published elsewhere (see Materials and Methods).  
2.1.3 Materials and Methods  
2.1.3.1 Study Design  
Study design, methods, and data analysis plan are described in detail in the study protocol 
published by Holtmann et al., (2014). Patients were recruited and treated in ﬁve German universi-
ty-based outpatient departments for child psychiatry/psychotherapy. All local ethics committees 
approved the study. Patients’ assent was obtained by using age-appropriate information and their 
parents or guardians gave written informed consent. Figure 2 depicts the design and study ﬂow. 
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Figure 2. Study flow (modified from Holtmann et al., 2014). 
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2.1.3.1.1 Study Groups  
Inclusion criteria comprised age from 7 to 9 years, and a diagnosis of ADHD combined 
type according to DSM-IV TR veriﬁed in a semi-structured interview under the supervision of 
clinical psychiatrists/licensed psychologists (Delmo et al., 1998). In the case of positive screen-
ings for comorbid symptoms assessed by the Child Behavior Checklist (CBCL; Arbeitsgruppe 
Deutsche Child Behavior Checklist, 1998), corresponding parents’ rating scales were applied 
(Döpfner and Lehmkuhl, 2000; Döpfner et al., 2006). Exclusion criteria consisted of a diagnosis 
of bipolar disorder, psychosis, serious obsessive-compulsive disorder, chronic severe tics or Tou-
rette syndrome, major neurological or physical illness, acute suicidal tendencies, pharmacothera-
py for severe anxiety, mood disorders and psychosis, IQ below 80, lack of German-language 
proﬁciency in the child or primary caregiver, no telephone, pregnancy and lactation, and current 
participation in other clinical trials. As the interventions were considered an add-on to treatment 
as usual pharmacotherapy for ADHD, Oppositional Deﬁant Disorder and Conduct Disorder were 
allowed. Patients were randomly assigned in a 1:1 ratio with varying block size to either the ex-
perimental or the control group. This assignment was realized by a computer-generated, web-
based tool provided by the Interdisciplinary Center for Clinical Trials (IZKS) Mainz. Randomiza-
tion was stratiﬁed per trial site and sex. Medical consultants rating clinical impairments were 
blinded. Participants were not blinded, because they were instructed according to their group as-
signment. Parents were not informed about treatment allocation but as the children were given 
instructions according to their treatment group, parents could infer their child’s group assign-
ment. 
2.1.3.1.2 Procedures 
After screening, there was a washout period of 2 weeks for children with psychostimu-
lants and 4 weeks for participants with atomoxetine. Pre-tests and post-tests 2 were conducted 
without medication. After the pre-test, children resumed their medication until completion of 
post-tests 1. The main outcome, therefore, was assessed by changes in post-tests 2 compared to 
pre-tests (see Figure 2). 
Participants received 25 training sessions within 3 months with two to three sessions per 
week. After session 12, there was a break of 4–6 weeks. Such a break has become standard in 
clinical NF studies to disburden the patients from the demanding training schedule with two to 
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three sessions per week and to give him/her the opportunity to practice self-regulation in every-
day life (transfer). 
2.1.3.1.3 Experimental Group: NF of SCP 
SCPs are very slow shifts in the EEG near to 0 Hz, typically generated in an event-related 
design for several seconds. A negative shift reduces the excitability of the underlying cortical 
area while a positive shift is understood as inhibition of excitation and/or consummation of ener-
gy. As event-related potentials, they prepare adequate cognitive as well as motor responses. In the 
feedback paradigm, participants were prompted to either produce negative (reducing the excita-
bility threshold of the underlying cortex) or positive shifts (inhibition of excitation) in a random-
ized order. After session 12, the ratio of negativity to positivity trials was increased from 50 to 
80%. The convention in SCP training so far has been to train and reinforce both polarities to im-
prove self- regulation, but particularly toward the end focus on that polarity which is thought to 
be related to the disease (e.g., Strehl et al., 2006). As the neurophysiological proﬁle of patients 
with ADHD indicates hypoactivation of cortical excitation thresholds, the training of negative 
shifts is thought to be more important. 
2.1.3.1.4 Control Group: Feedback of electromyographic Coordination of the Supraspinatus 
Muscles 
As a semi-active control condition, EMG feedback of coordination in the supraspinatus 
muscles was chosen. Participants were instructed either to contract or to relax the left relative to 
the right supraspinatus muscle. This protocol was chosen to induce diﬀerential EMG control cor-
responding to the “polarities” comparable to the NF condition, without requiring simple relaxa-
tion or tension. This allowed us to use the same device and the same representation of the feed-
back signal on the screen. We did not choose a standard EMG feedback protocol because the con-
trol condition should be as unspeciﬁc as possible but include the possibility to learn self-
regulation, i.e., the unspeciﬁc variable of any biofeedback treatment. 
2.1.3.1.5 Common components of Behavior Therapy in both Groups 
All interventions took place in outpatient clinics. Setting, training devices, electrode mon-
tage, feedback and transfer trials, number of sessions, transfer exercises, and the possibility to 
earn tokens were the same in both groups. The treatment schedule (Figure 3) for each session 
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comprised four blocks of 40 trials each. Each trial lasted for 10 s (2 s baseline and 8 s feedback 
and depicting a “sun” after successful trials). In all sessions, the third block operated without con-
tinuous feedback; only the sun was shown at the end if the trial had been successful (Figure 3). 
These trials were part of several measures to carry over self-regulation skills to everyday life: 
During the break following session 12, patients were asked to practice self-regulation at home 
using small memo cards depicting the screen during a task. In addition, self-regulation could be 
trained with the help of a video showing a sequence of both positivity and negativity trials. After 
each of the 10 ﬁnal sessions, the children did part of their homework in the lab under the trainer’s 
supervision making use of the memo cards. As a reward for their participation and for good co-
operation children could earn tokens. Whenever a certain number was achieved, tokens were 
swapped for vouchers or small gifts. 
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Figure 3. Treatment schedule. 
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2.1.3.2 Acquisition of EEG- and EMG Signals 
EEG and EMG were recorded and fed back with a multichannel ampliﬁer (THERA 
PRAX R neuroConn GmbH, Ilmenau, Germany). The EEG electrode was placed at Cz, refer-
enced against the mastoid behind the right ear. Four electrodes were used to record the vertical 
and horizontal electrooculogram (EOG) and one electrode behind the left ear was used as ground. 
EMG was recorded with one electrode per shoulder placed at the upper area of the right and left 
supraspinatus muscle. Oﬀ-line analyses were performed with the Brain Vision Analyzer (Version 
2.0, Brain Products, Gilching, Germany). For training data, EEG was ﬁltered oﬀ-line using a 0.01 
Hz high cut-oﬀ ﬁlter (12 dB/octave) plus 50 Hz notch ﬁlter, referenced with one mastoid, fol-
lowed by ocular correction (Gratton, Coles, & Donchin, 1983). Data were segmented for both 
tasks (positive and negative SCP shifts). Artifacts were rejected semi-automatically if trials were 
over ±150 µV. Remaining artifact-free trials were averaged. The average was exported using the 
last 4–8 s of every trial that lasted 8 s. Each center was guided by a detailed manual to ensure 
equal handling of participants, testing, and treatment. Center representatives met for an initial 2-
day training course and on a regular basis thereafter. Supervision visits took place to guarantee 
compliance with the manual.  
2.1.3.3 Outcomes 
Psychometric properties of all pre-speciﬁed measures are reported in Holtmann et al., 
(2014). For the present ﬁrst paper outcomes are reported as changes from pre-test to post-test 2 
(after washout of medication, deﬁned a priori as the primary endpoint to avoid residual medica-
tion confounds, and to focus on stable or sustained SCP-NF eﬀects). Apart from IQ and cortical 
self-regulation, a detailed analysis of learning parameters, electrophysiological, neuropsychologi-
cal outcomes, and 6-month follow-up data will be reported elsewhere. The primary endpoint was 
the parent-rated ADHD symptom severity assessed using the mean global score of the German 
ADHD rating scale (24). The scale consists of 20 items assessing the severity of inattention, hy-
peractivity, and impulsiveness. Each item, corresponding to one of the DSM-IV diagnostic crite-
ria, is rated on a 4-point scale (0 = never or rarely; 1 = sometimes; 2 = often; 3 = very often). 
Secondary endpoints were: 
– Parents’ ratings of ADHD subdomains (inattention, hyperactivity, impulsivity; Dö-
pfner et al., 2006).  
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– Teachers’ ratings of ADHD symptoms (global score and subdomains; Döpfner et al.,  
2006). 
– The Clinical Global Impression-Improvement (CGI-I) responder status assessed by a 
blinded clinician (Guy, 1976). 
– Comorbid symptoms [parents’ and teachers’ ratings via the Strengths and Diﬃculties   
Questionnaire (SDQ); Woerner, Becker, & Rothenberger, 2004]. 
– Full-scale IQ [indicated by its percent rank; measured with parallel versions of the Col-
oured Progressive Matrices (CPM) to minimize test-retest eﬀ ects; Bulheller and Häck-
er, 1998. 
– Quality of life assessed via the global score of the revised German Kid-KINDL(R) (Ra-
vens-Sieberer & Bullinger, 1998). 
– Parents’ satisfaction with therapy: unpublished questionnaire developed by the Institute 
of Medical Psychology and Behavioral Neurobiology, Tübingen (2004). Parents sub-
mitted these questionnaires directly to the IZKS to guarantee anonymous handling and 
thereby avoiding responses driven by social desirability. 
 – Adverse events (AE) and serious adverse events (SAE): at each contact participants 
were asked to report any AE and their severity using open questions. 
As covariates, we assessed parenting style and parents’ expectations (Arnold et al., 1993) 
at screening. Self-regulation of EEG during training sessions was assessed to evaluate the 
speciﬁcity of NF. 
2.1.3.4 Statistical Analysis 
The methodology for processing and analyzing the data was documented in a Statistical 
Analysis Plan (SAP) dated and maintained by the IZKS responsible for data management, moni-
toring, and analysis (for details, see Holtmann et al., 2014). Sample size calculation for the pri-
mary endpoint was based on an estimation of eﬀ ect sizes derived from the SCP-NF study by 
Heinrich et al., (2004) using the same outcome measure. Expecting a mean ADHD score of 1.2 at 
post-test 2 in the NF group and of 1.5 in controls with a common SD of 0.55 a sample size of 72 
per group was required to achieve a power of 90% (α = 0.05, two-sided t-test). Data were ana-
lyzed primarily in the modiﬁed intention-to-treat (mITT) population, comprising all randomized 
patients except those who received no treatment due to violation of inclusion criteria. Supportive 
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analysis was performed in the per-protocol (PP) population, comprising all mITT patients who 
did not meet any of the following criteria: violation of inclusion or exclusion criteria, major devi-
ations from the visit schedule, and lack of compliance during treatment sessions. Safety parame-
ters were analyzed in the safety population, comprising all participants with at least one feedback 
session. The primary outcome was tested by an analysis of covariance (ANCOVA) with treat-
ment, trial site, sex, baseline ADHD score, baseline ADHD medication, parenting style, and par-
ents’ expectations as covariates. Missing ADHD scores were imputed according to the baseline 
observation carried forward (BOCF) method. This is usually considered a conservative approach 
to handle missing data since patients with missing values are treated as treatment failures. This 
conservative approach is supposed to avoid too positive results when many patients from the NF 
treatment group dropout who do not improve or even get worse. Therefore, the analysis was re-
peated with a multiple imputation approaches. Additional covariates were used to create 10 com-
plete datasets. Those datasets were analyzed by the same ANCOVA model as the primary analy-
sis. Afterward, the results were combined by Rubin’s rules. Secondary analyses comprised AN-
COVAs (analogously to the primary analysis) for differences in ADHD global and subdomain 
scores (teachers’ ratings), t-tests for differences in ADHD global scores (parents’ ratings, teach-
ers’ ratings), SDQ subscales, IQ, quality of life, and parents’ satisfaction with therapy. For the 
binary variable Clinical Global Impression (CGI) McNemar’s tests were used to test for differ-
ences between time points within groups, and chi-squared tests were used for differences between 
groups. Results of all statistical tests except for the primary analysis must be interpreted in an 
exploratory manner. To assess the magnitude of treatment effects, between-treatment eﬀ ect sizes 
were calculated by dividing the treatment-group differences (including the BOCF method if indi-
cated) by the pooled standard deviation at pre-test. Within-treatment effect sizes were calculated 
by dividing the mean of changes by the standard deviation at pre-test. To assess the extent and 
speciﬁcity of SCP self-regulation, the mean amplitude of SCPs and mean self-regulation perfor-
mance (percentage of correct trials) were averaged for training sessions 2 + 3, 10 + 11, 14 + 15, 
and 23 + 24. These session averages were selected in line with previous work (Strehl et al., 
2006). This selection provides robust estimates of regulation performance and learning while 
excluding the undesired inﬂuences of novelty or expected completion in the initial and ﬁnal ses-
sions of each training half. SCP amplitude (µV) was analyzed using group by task × sessions 
(only the four session averages during training to minimize the number of dropouts) repeated-
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measures ANOVAs. Self-regulation performance was analyzed using a group by sessions (the 
four session averages during training plus post 2 performance) repeated-measures ANOVA. SCP 
amplitude and self-regulation performance were analyzed separately for thefeedback and transfer 
condition. 
An independent data monitoring and safety board supervised the conduct of the study. 
The trial was registered under Current Controlled Trials ISRCTN76187185 (5 February 2009). 
2.1.4 Results  
2.1.4.1 Patients 
A total of 174 participants were recruited between September 2009 and January 2013 for screen-
ing, 150 of whom were allocated to one of the two treatment groups. In NF 60 and in EMG 51 
participants completed treatment and took part in all assessment points. The CONSORT ﬂow 
diagram is depicted in Figure 4. The mITT population comprised 75 participants in NF and 69 in 
EMG. Baseline characteristics are depicted in Table 1. There were no diﬀ erences between groups 
in any of these variables. The safety population comprised 96% of the mITT population for NF 
and 98.55% for EMG; the PP population consisted of 59% for NF and 58% for EMG. The main 
reason for violation of the protocol was delay of post-tests 2, which occurred in 41% of NF and in 
42% of EMG mITT populations. NF had 16% dropouts, EMG 17%, with most dropouts occur-
ring between pre-test and session 12. A comparison between dropouts and non-dropouts yielded 
the following differences: lower level of education of fathers (p = 0.03—chi-squared test), fewer 
parents living together (p = 0.027—chi-squared test), and more severe oppositional deﬁant disor-
der (p = 0.033—t-test) in those who did not complete the study. 
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Figure 4. CONSORT flow diagram 
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Table 1. Baseline characteristics of participants 
    Neurofeedback N= 75   EMG feedback N= 69 
Variable 
 
Mean SD 
 
Mean  SD 
Age (in years) 
 
8.6 0.92 
 
8.57 0.88 
ADHD global score 1.84 0.045 
 
1.78 0.47 
KINDL® Quality of Life 67.5 8.9 
 
68.6 9.6 
CPM (percentage rank) 63.4 27 
 
65.5 27 
CBCL t-value 
      Global 
 
63.6 8.4 
 
63.2 7.8 
Externalizing problems 66.3 9.4 
 
64.8 9.4 
Internalizing problems 62.2 9.5 
 
62.4 9.3 
    N Percent   N Percent 
CBCL Comorbidity* 
     Oppositional defiant disor-
der 31 41.33 
 
32 46.36 
Conduct disorder 0 0.00 
 
1 1.45 
Depression 
 
11 14.66 
 
8 11.59 
Dysthymia 
 
5 6.67 
 
3 4.35 
Separation anxiety 3 4.00 
 
5 7.25 
General anxiety disorder 18 24.00 
 
18 27.69 
Social phobia 
 
4 5.33 
 
8 11.59 
Specific pho-
bia 
 
4 
  
6 8.64 
Sex 
     Femal 
 
14 18.67 
 
11 15.94 
Male 
 
61 81.33 
 
61 84.06 
CGI-S 
  
 
   Normal/Bordeline ill 3 5 
 
3 5.36 
Mild/Moderately ill 29 48.33 
 
29 45.78 
Marked/Severely ill 28 46.67 
 
24 42.86 
Missing 
 
15 
  
13 
 ADHD medication prior to 
study 34 45.33   28 40.58 
CGI, Clinical Global Impression-Severity; CBCL, Chiuld Behavior Checklist; *disorder-specific 
parent ratings 
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2.1.4.2 Primary Outcome 
NF was signiﬁcantly superior to EMG in reducing ADHD core symptoms as rated by par-
ents with a diﬀerence of 0.17 (95% CI 0.02–0.30, F(1) = 5.30, p = 0.02). ANCOVA yielded no 
impact on sex, trial site, medication status at baseline, parenting style, and parents’ expectations 
on the reduction of ADHD core symptoms as rated by parents (Table 2). The more pronounced 
ADHD symptoms were at pre-test the larger was their reduction. The sensitivity analysis with the 
PP population (N = 84) yielded similar results (Supplementary Table 8). The multiple imputation 
approaches revealed similar results: the diﬀerence between treatments was 0.22 (95% CI 0.03–
0.4), p = 0.02. The diﬀerence of changes in the ADHD global score between groups, as compared 
by a t-test, was signiﬁcant for the mITT population (BOCF), at p = 0.01 (NF mean −0.35, SD 
0.42; EMG mean −0.17, SD 0.43), and yielded an ES of d = 0.57 without BOCF and 0.40 with 
BOCF. Within-group analyses revealed eﬀect sizes of 0.78 for NF and 0.35 for EMG. Global 
score changes from pre-test to post-test 2 are depicted in Figure 5. 
 
Table 2. Primary analysis: Differences in ADHD global score (parents’ ratings; post-test 2 minus 
pre-test between groups; mITT population, ANCOVA, baseline observation carried forward); df, 
degree(s) of freedom. 
 Adjusted mean (95% CI) p F df 
EMG-Feedback -0.1338 (-0.259 / -0.008)    
Neurofeedback -0.2987 (-0.416 / -0.181)    
Difference between treatments 0.1649 (0.023 / 0.301)    
Treatment  0.0230 5.30  1 
Baseline ADHD global score  0.0008 11.84 1 
Sex  0.1879 1.75 1 
Trial site  0.5951 0.70 4 
Baseline ADHD medication (yes/no)  0.3016 1.08 1 
Parenting style  0.8007 0.06 1 
Parents’ expectations  0.4154 0.67 1 
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2.1.4.3 Secondary Outcomes 
2.1.4.3.1 Parents´Ratings of ADHD Subdomains 
Data for all scales at pre-test and post-test 2 are reported in Table 3 (BOCF). For results 
without BOCF, see Supplementary Table 9. 
Table 4 shows the adjusted mean diﬀerence of change scores post-test 2 minus pre-test 
between groups (BOCF). Both groups improved in the subdomain hyperactivity, although no 
diﬀerence between groups was observed. Parents’ ratings indicated superior improvements in the 
NF group for the subscales impulsivity (p = 0.02) and inattention (p = 0.02) with medium eﬀect 
sizes. Similar to the primary analysis none of the covariates had an impact on treatment diﬀer-
ences. 
2.1.4.3.2 Teachers´Ratings of ADHD Core Symptoms 
The diﬀerence between groups based on teachers’ ratings of ADHD global scores (mITT 
population, ANCOVA, BOCF; Supplementary Table 10) was not signiﬁcant [treatment diﬀer-
ence 0.04, 95% CI −0.12 to 0.21, F(1) = 0.25, p = 0.62]. ANCOVA yielded a signiﬁcant within-
group diﬀerence for NF (mean change of −0.16; 95% CI −0.3 to −0.02) but not for EMG (mean 
change of −0.11; 95% CI −0.26 to 0.04). Data for all scales at pre-test and post-test 2 are reported 
in Table 5 (BOCF); for results without BOCF, see Supplementary Table 11. Post hoc t-tests for 
changes from pre-test to post-test 2 in global score and subscores yielded no diﬀerences between 
groups (see Table 6). According to within-group analyses, improvements in global scale, inatten-
tion, and impulsivity were observed for NF only, albeit with small eﬀect sizes.  
 
 
 
 
 
 
 
 
Figure 5. Least square means of ADHD global score changes from pre-test to post-test 2 (parents´ 
and teachers´ ratings; mITT population, ANCOVA, baseline observation carried forward) 
Treatment 
Parents: EMG Feedback 
              Neurofeedback 
Teachers: EMG Feedback 
  
 
              Neurofeedback 
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Table 3. Parents´ADHD ratings (mITT population N= 144, BOCF) 
  NF   EMG Total 
   Pre-test   Post-test 2   Pre-test   Post-test 2 Pre-test Post-test 2 
 Hyperactivity 
          N 72 
 
73 
 
67 
 
68 139 141 
 Mean(SD) 1.54 (0.63) 1.22 (0.71) 1.52 (0.67) 1.33 (0.66) 1.53 (0.64) 1.28 (0.68) 
Missing 3 
 
2 
 
2 
 
1 5 3 
 Impulsivity 
          N 72 
 
73 
 
67 
 
68 139 141 
 Mean(SD) 1.93 (0.65) 1.59 (0.65) 1.8 (0.78) 1.71 (0.76) 1.87 (0.73) 1.65 (0.71) 
Missing 3 
 
2 
 
2 
 
1 5 3 
 Inattention 
          N 72 
 
73 
 
67 
 
68 139 141 
 Mean(SD) 2.03 (0.53) 1.64 (0.59) 1.97 (0.51) 1.8 (0.48) 2.00 (0.52) 1.72 (0.54) 
Missing 3 
 
2 
 
2 
 
1 5 3 
Global score* 
         N 72 
 
73 
 
67 
 
68 139 141 
Mean(SD) 1.84 (0.49) 1.49 (0.55) 1.78 (0.47) 1.62 (0.5) 1.81 (0.46) 1.55 (0.53) 
Missing 3   2   2   1 5 3  
 *Global score could not be assessed if more than two items in subscales were missing. 
 
Table 4. Adjusted mean differences in ADHD subdomain scores (parents´ratings; post-test 2 mi-
nus pre-test between groups; mITT population, ANCOVA, BOCF) 
 
  
Neurofeedback N=75 (23 BOCF) EMG feedback N= 69 (20 BOCF) Difference 
Variables 
 
Mean 95% CI Mean 95% CI Mean 95% CI p ES 
Hyperactivity 
 
-0.28 -0.42/-0.13 0.17 -0.33/-0.02 0.11 -0.07/0.28 0.23 0.18 
Impulsivity 
 
-0.30 -0.45/-0.15 -0.09 -0.25/0.07 0.21 0.03/0.39 0.05 0.34 
Inattention 
 
-0.31 -0.44/-0.18 -0.13 -0.27/0.01 0.18 0.03/0.36 0.02 0.40 
 
2.1.4.3.3 Clinical Global Impression 
Clinicians did not observe signiﬁcant diﬀerences between groupsregarding the responder 
status. At post-test 2 the percentage of responders was 27% (NF) and 26% (EMG). The analysis 
was limited due to a large proportion of missing values (about 40% of the mITT population in 
both groups). 
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2.1.4.3.4 Comorbid Symptoms (SDQ) 
No diﬀerence between groups was observed regarding changes in comorbid symptoms be-
tween pre-test and post-test 1, as assessed with parents’ ratings. Children were rated as slightly 
improved in both groups. 
2.1.4.3.5 Full Scale IQ (CPM) 
A signiﬁcant diﬀerence between groups was observed regarding the change in full scale 
IQ from pre-test to post-test 2 (p = 0.04, ES = −0.37). While the percentage rank in the EMG 
group declined from pre- (mean 65.5, SD 25.7) to post-assessment (mean 59.9, SD 31.4) it im-
proved in the NF group from pre- (mean 63.4, SD 28.0) to post-assessment (mean 65.7, SD 28.0). 
2.1.4.3.6 Quality of Life [KINDL(R)] 
There was no change from pre-test to post-test 2. Scores in both groups ranged from 68 to 
72, which is below the standard values of healthy children (Ravens-Sieberer and Bullinger, 
1998). 
2.1.4.3.7 Parents´Satisfaction with Treatments 
There were no diﬀerences in parents’ ratings regarding their satisfaction with the treat-
ment. Mean values were 4.1 (SD 1.6) for NF and 4.4 (SD 1.4) for EMG on the 6-point Likert 
scale. 
2.1.4.3.8 Adverse Events and Serious Adverse Events 
In the safety population (N = 140) 119 AE were reported. At least one AE was reported in 
33% of NF participants and 35% of EMG participants. A possible causal relation with the treat-
ment was stated in 4 (6%) of NF participants and 5 (7%) of EMG participants. These children 
reported headaches (N = 4, both groups), skin reactions (n = 3, NF), myalgia (n = 1, EMG), and 
nausea (n = 1, EMG). SAE were reported for two children in each group (deterioration of ADHD: 
n = 2, EMG; n = 1, NF; psychological trauma after traﬃc accident: n = 1, NF). One of these chil-
dren (EMG group) was withdrawn from the study because ADHD symptoms deteriorated. 
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Table 5. Teachers´ADHD ratings (mITT population N= 144, BOCF) 
  NF   EMG   Total 
  Pre-test Post-test 2 
 
Pre-test Post-test 2   Pre-test Post-test 2 
Hyperactivity 
        N 68 70 
 
63 64 
 
131 134 
Mean(SD) 1.15(0.81) 1.05 (0.79) 
 
1.02 (0.85) 1.02 (0.77) 
 
1.09 (0.83) 1.04 (0.78) 
Missing 7 5 
 
6 5 
 
13 10 
Impulsivity 
        N 68 70 
 
63 64 
 
131 134 
Mean(SD) 1.41 (0.95) 1.24 (0.94) 
 
1.31 (0.95) 1.27 (0.92) 
 
1.36 (0.95) 1.25 (0.93) 
Missing 7 5 
 
6 5 
 
13 10 
Inattention 
        N 68 70 
 
63 64 
 
131 134 
Mean(SD) 1.69 (0.70) 1.59 (0.70) 
 
1.68 (0.72) 1.60 (0.68) 
 
1.69 (0.71) 1.60 (0.69) 
Missing 7 5 
 
6 5 
 
13 10 
Global score* 
       N 65 69 
 
63 61 
 
125 130 
Mean(SD) 1.48 (0.64) 1.34 (0.68) 
 
1.38 (0.71) 1.32 (0.71) 
 
1.43 (0.67) 1.3 (0.66) 
Missing 10 6   9 8   19 14 
*Global score could not be assessed if more than two items in subscales were missing. 
 
Table 6. Mean differences (SD) in ADHD global and subdomain scores (teachers´ratings; post-
test 2 minus pre-test between and within groups; mITT population, BOCF). 
    Within group analysis         Between 
 
 
Neurofeedback N=75 (23 BOCF)   EMG feedback N= 69 (20 BOCF) group analysis 
Variables Mean SD p  ES   Mean 95% CI p  ES p ES 
Hyperactivity -0.11 0.7 0.22 0.13 
 
-0.01 0.56 0.86 0.01 0.4 0.11 
Impulsivity -0.2 0.7 0.03 0.21 
 
-0.06 0.62 0.45 0.06 0.24 0.15 
Inattention -0.13 0.53 0.04 0.19 
 
-0.08 0.43 0.16 0.11 0.51 0.08 
Global score* -0.15 0.54 0.03 0.23   -0.07 0.41 0.19 0.1 0.36 0.12 
*NF: N=47; EMG; N=39 because global score could not be assessed if more than two items in 
subscales were missing. 
 
2.1.4.3.9 Self-Regulation of EEG 
For the SCP amplitude averaged over all training sessions, a signiﬁcant interaction was observed 
between shift direction (trial polarity) and group (p ≤ 0.0001, η 2 = 0.18). Only the SCP-NF 
group diﬀerentiated between EEG polarities (p < 0.0001), achieving negative mean amplitudes in 
negativity trials and positive amplitudes in positivity trials. These correct polarities were only 
Empirical studies 
 
42 
achieved in the feedback condition, while the transfer condition did not show signiﬁcant diﬀer-
ences between polarities or groups (see Figure 6). Repeated-measures ANOVA for self-
regulation performance during feedback trials revealed a signiﬁcant main eﬀect of session (p < 
0.001, η 2 = 0.067) and a group × session interaction (p < 0.006, η 2 = 0.054). The EMG-NF 
group achieved higher self-regulation rates compared to the SCP-NF group (p < 0.0001). Post 
hoc comparisons showed that the SCP- NF group improved signiﬁcantly self-regulation at post 2, 
and the EMG group improved performance over sessions, however, there the last session was not 
diﬀerent from the ﬁrst one. For the transfer condition, repeated-measures ANOVA showed a 
signiﬁcant main eﬀect of session (p < 0.001, η 2 = 0.044) but no group × session interaction. The 
EMG group achieved higher self-regulation rates compared to the SCP-NF group (p < 0.0001). 
Post hoc comparisons showed that only the EMG group enhanced performance over time (see  
Figure 7).  
2.1.4.3.10 Self-Regulation Performance and its Relation to Clinical Changes 
To assess the impact of self-regulation performance on the clinical outcome we grouped 
participants into learners and non-learners based on the sign of their regression slope for the 
feedback and the transfer condition separately. For the feedback condition, 67.9% were classiﬁed 
as learners in the SCP-NF group, while 71.1% in the EMG group were classiﬁed as learners. For 
the transfer condition, 53.7% of the SCP-NF group and 73.7% of the EMG group were classiﬁed 
as learners. No signiﬁcant correlation between performance and clinical outcome was obtained 
for either group on the primary parent-rated outcome or the corresponding secondary teacher rat-
ed total score. 
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Figure 6. Self-regulation of SCP amplitude by group (NF vs. EMG) and task (polarity; positivity 
vs. negativity). *p<.05**p<.01. 
 
 
Figure 7. Self-regulation performance during feedback and transfer trials: (A) SCP-NF group and 
(B) EMG-NF group. *p<.05**p<.01. 
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2.1.4.3.11 Post hoc Analyses 
Response status was deﬁned based on CGI; however, there were too many missing data 
for the analysis. We, therefore, assessed the responder rates based on a >25% improvement on 
the parent-rated ADHD global score from pre-test to post-test 2. As a result, NF yielded a re-
sponder rate of 52% and EMG of 35% (mITT population). Based on BOCF analysis we observed 
38% responder after NF and 25% after EMG feedback. To explore possible reasons for the 
diﬀerence between parents’ and teachers’ ratings we computed an independent samples t-test. 
Teachers rated symptoms as less severe than parents did (see Table 7). 
 
Table 7. Comparison of parents’ and teachers’ ratings ADHD global 
  
Parents Teachers p 
  
Mean SD Mean SD 
 NF pre-test 
 
1.84 0.45 1.48 0.64 0.0002 
NF post-test 2 minus pre-
test -0.49 0.42 -0.21 0.54 0.01 
EMG pre-
test 
 
1.78 0.47 1.38 0.71 0.0003 
EMG post-test 2 minus 
pre-test -0.27 0.5 -0.11 0.51 0.28 
 
 
2.1.5 Discussion 
This is the ﬁrst randomized controlled clinical trial to investigate the speciﬁcity of SCP 
feedback in children with ADHD, and the largest study on an outpatient ADHD sample treated 
with NF. We compared two treatments (SCP-NF and EMG feedback) using identical training 
setups to control for unspeciﬁc eﬀects. For the ﬁrst time in NF research, a BOCF approach was 
used to handle missing data. This study conﬁrmed speciﬁc positive eﬀects of SCP-NF on parent-
rated ADHD symptom severity, with a signiﬁcant greater decrease in symptoms compared to 
EMG feedback. Sex, trial site, medication, parenting style, and parents’ expectation had no im-
pact on the ADHD score change. Sensitivity analyses with multiple imputations and with the PP 
population generated comparable results. These results are in line with previous ﬁndings of trials 
comparing NF to semi-active control groups (Arns et al., 2014). Symptom severity, comorbidity 
pattern, and age of our sample match that of the gold-standard MTA-study and can be regarded as 
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representative for children referred for outpatient ADHD treatment (The MTA Cooperative 
Group, 1999). Our study set out to assess both speciﬁc and unspeciﬁc eﬀects of NF. An important 
hint for speciﬁcity is the demonstration of successful SCP self-regulation for children in the SCP-
NF group only. The signiﬁcant symptom improvement in NF may be regarded as a conﬁrmation 
of speciﬁc eﬀects of SCP-NF. The lack of SCP regulation during the transfer condition in the NF 
group may suggest either limited or delayed transfer and a restricted generalization into everyday 
life. Here we should wait for follow-up results as it was shown previously for patients with epi-
lepsy (Kotchoubey et al., 1997) and children with ADHD (Strehl et al., 2006) that performance in 
transfer trials improved substantially 6-month after the end of training. In addition, our results 
also point to a strong inﬂuence of unspeciﬁc variables on treatment outcome. We compared two 
treatments using identical conditions regarding tasks, time schedule, possible amount of rein-
forcement, and interaction. Children in the semi-active control group underwent the same intense 
treatment in an identical setting. In feedback treatments, contingent reinforcement of regulation 
of a physiological parameter improves self-eﬃcacy and coping (Holroyd et al., 1984). Thus, 
EMG feedback may have an impact on ADHD symptoms (by improving self-regulation skills) 
even though there is no known direct relation between control of EMG activity and the neurobio-
logical pathology of ADHD. It has to be noted that the type of EMG feedback used in this study 
is diﬀerent from the EMG feedback protocols used previously in a couple of studies in the treat-
ment of ADHD (for a review, see Arnold, 2001), showing some eﬀects compared to conditions 
such as sham feedback, waiting list, keeping children busy by just playing or listening to a story-
teller. Bakhshayesh et al., (2011) who used EMG feedback as a control condition for theta/beta 
feedback report some but smaller eﬀects for EMG feedback compared to frequency band NF. A 
comparison of tomographic NF with EMG feedback yielded only small diﬀerences between 
treatments with a tendency for EEG feedback with better improvements (Maurizio et al., 2014). 
While the former study trained relaxation of muscles our participants had to succeed in the simul-
taneous relaxation and tension of two diﬀerent muscles similar to the latter study. This diﬀeren-
tial EMG feedback is far away from standard EMG feedback relaxation protocols aiming to re-
duce hyperactivity, a core symptom of ADHD. It, therefore, should be of limited speciﬁc 
inﬂuence on ADHD symptoms. The ﬁnding of similarly reduced hyperactivity according to par-
ents’ ratings in both groups ﬁts into this consideration of unspeciﬁc eﬀects. The rather small (0.40 
with BOCF) or medium (0.57 completer) eﬀect size of the between-group comparisons should be 
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discussed in several respects. First, due to the considerable unspeciﬁc eﬀects in the semi-active 
control group, the clinical eﬀects of NF (which also include unspeciﬁc eﬀects) may have been 
underestimated. NF-studies in ADHD with waiting list controls tend to yield much higher eﬀect 
sizes than those with active or semi-active control conditions (see Cortese et al., 2016). In addi-
tion, none of the NF studies published so far used the rather conservative BOCF method. There-
fore, a comparison with those studies should consider the medium ES for the completers. Fur-
thermore, it must be noted that a meta-analysis of cognitive trainings in ADHD yielded an ES of 
0.37 (Cortese et al., 2015). Similarly, for behavioral interventions, the meta-analysis reported an 
ES of 0.35 (Daley et al., 2014). In addition, we analyzed post hoc within ES for our groups. Here, 
medium to large eﬀect sizes of 0.78 (BOCF) and 1.09 (completer) for NF were observed, while 
the eﬀect sizes for EMG were small with 0.35 (BOCF) and 0.48 (completer). According to teach-
ers, who can be regarded as possibly blinded raters, there was no group eﬀect in favor of NF. 
This is of considerable concern in the light of a recent meta-analysis highlighting smaller eﬀect 
sizes when applying probably blinded vs. non-blinded ratings (Cortese et al., 2016). Whether NF 
helps more or faster in the home setting than in school or whether teachers are less sensitive to 
change than parents are still unresolved questions. Similar to ﬁndings from other ADHD studies 
(e.g., Sollie, Larsson, & Mørch, 2013), teachers compared to parents rated children as being less 
aﬀected. This may have contributed to the non-signiﬁcant ﬁndings since more pronounced base-
line ADHD symptoms were associated with a better response to NF. Within-group analysis of our 
teachers’ results revealed eﬀects of NF on the global ADHD score, inattention, and impulsivity, 
while EMG feedback did not result in such signiﬁcant changes. A recent meta-analysis showed 
similar results of NF based on teacher ratings on inattention (Micoulaud-Franchi et al., 2014). 
Unfortunately, our study was not powered to detect diﬀerences between treatments based on 
teacher ratings, but the small eﬀect sizes could also suggest that the SCP-NF speciﬁc improve-
ments may be of limited signiﬁcance in school settings. This raises the possibility that more train-
ing sessions and transfer trials, or more sensitive blinded ratings may be needed for SCP-NF to 
produce clinically signiﬁcant improvement of ADHD symptoms in school settings. However, the 
observation that teachers judged the children as signiﬁcantly less aﬀected may put these consid-
erations into a diﬀerent perspective. If there is less clinical relevance perceived there may be less 
need for and awareness of change. As discussed by Cortese  et al. (2016), teachers may be less 
attentive to improvements or the instruments used should be complemented, e.g., by behavior 
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observation. Furthermore, teachers’ ratings being probably blind regarding treatment allocation 
are not necessarily more precise. Blinding does not validate ratings as superior per se. Recently, 
Janssen et al., (2016) reported reductions in theta power that were predictive of parents’ ratings of 
reduced inattention, whereas no such association was found for (probable blinded) teachers’ rat-
ings. 
Physicians or clinical psychologists not involved in the study rated about 27% of children 
in both groups as responders based on CGI ratings. The almost identical response rate in both 
groups supports the assumption of large unspeciﬁc eﬀects of the treatments. Unfortunately, there 
were about 40% missing values. Furthermore, the validity of the clinicians’ ratings is questiona-
ble, as some parents reported that the clinicians asked them about their own judgment and gave 
their ratings accordingly. To supplement the response ratings of clinicians, we determined how 
many parents described a reduction of ADHD total symptoms of more than 25% for their child. 
Here, 52% of NF and 35% of EMG children (mITT population) were rated as improved. This 
result is comparable to response rates reported by Gevensleben et al., (2009) with 52% for NF 
and 29% for the computer-based attention skills training. The a priori decision to deﬁne parents’ 
ratings as “primary” was not only based on methodological requirements. Parents observe many 
facets of their children’s everyday family, social and academic life, and suﬀer from impairment 
in all these areas. This may not only explain the more severe ratings compared to those given by 
teachers but also points to the ecological validity of their judgments. Although parents were not 
informed about treatment allocation, we cannot rule out that information given to them by their 
children may have aﬀected their ratings. Parents’ ratings were probably not blinded because chil-
dren were instructed diﬀerently according to treatment allocation. Blinding of patients and staﬀ 
may count as a gold standard of evidence-based medicine in drug research but may interfere in 
treatments where patients are expected to learn a certain behavior or skill. This holds true for 
psychotherapy in general and it is of utmost importance in feedback therapy aiming at the acqui-
sition of a self-regulation skill. Without knowing which parameter has to be trained the patient 
may lose time, motivation and precision (Surwit and Keefe, 1983). An important feature even in 
blinded designs is the control of expectations inﬂuencing the outcome of any treatment (Benedetti 
et al., 2005; Oken, 2008). In our study, parents’ expectations had no eﬀect on outcome. However, 
their satisfaction was high and did not diﬀer between treatments, again pointing to the impact of 
unspeciﬁc variables acting similarly in both groups. The assessment of expectations is a ﬁrst step 
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although the psychometric quality of the questionnaire we used is not yet assessed. We also con-
sidered that alternative control conditions where EEG activity unrelated to ADHD must be regu-
lated could have reduced perceptual awareness and allowed blinding. However, we were not 
aware of any EEG activity that is completely unrelated to ADHD on the one hand and would do 
no potential harm on the other hand. 
In addition to comparing the reduction of symptoms between groups self-regulation, per-
formance and its correlation with clinical outcome was analyzed. This analysis yielded mixed 
results: in the absence of signiﬁcant correlations between self- regulation and clinical outcome 
(global score) the (amount of) speciﬁcity remains questionable. On the other hand, more children 
in the EMG group than in the NF-group learned to improve self-regulation, consistent with the 
results of Maurizio et al., (2014). Subsequently, better self-regulation and learning resulted in 
more positive reinforcement (i.e., more frequent reinforcement following successful trials) for 
children of the EMG group. As learning to self-regulate is acknowledged as an important un-
speciﬁc variable in biofeedback, one could have expected more clinical improvement and superi-
or outcomes in the EMG group. This was not the case. Therefore, the clinical advantage of NF is 
unlikely due to unspeciﬁc eﬀects only. Given the many ways of analyzing learning (e.g., within 
sessions learning vs cross sessions as well as pre–post diﬀerences in spontaneous as well as 
event-related brain activity (Gruzelier, 2014; Maurizio et al., 2014; Zuberer et al., 2015) further 
analyses, including follow-up observations will give more insight in this important matter. For 
the ﬁrst time, AE and SAE of SCP-NF were investigated with the help of the WHO Adverse Re-
action Terminology, included in the Medical Dictionary for Regulatory Activities for clinical 
studies (MedDRA R, Version 16). The treatments were feasible and AE related to the treatment 
were observed in only a few children. While one child of the EMG group had to be withdrawn 
from the study because his symptoms deteriorated, the other AE in children of both groups remit-
ted quickly. The drop-out rate was similar to previous NF-studies with comparable duration of 
treatment. Most drop-outs were observed between pre-test and end of ﬁrst treatment phase. In 
accordance with evidence on ADHD treatment utilization adherence may have been hampered by 
personal and family characteristics of dropouts (higher level of oppositional symptoms, lower 
paternal level of education, more single parents) (Corkum et al., 2015). Such families may re-
quire special attention when behavioral interventions are planned. A diﬀerence in the change of 
the full scale IQ was observed between groups. While there was a slight increase in NF, 
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performance of EMG participants declined. This may be due to EMG children investing less 
eﬀort in the test, and to SCP-NF releasing attentional resources (Strehl, Kotchoubey, Martinetz, 
& Birbaumer, 2011). Earlier studies have already reported improvements in children with ADHD 
after SCP-NF. We have moved a step forward in answering questions regarding speciﬁcity, 
eﬃcacy and feasibility with this study. We included the largest sample treated with NF to date, 
used a semi-active control condition with an identical setting, a conservative statistical approach 
(BOCF), and SCPs as target for NF, which has been identiﬁed as a stable marker of ADHD. Ma-
jor limitations of the present study are the lack of power regarding teacher ratings, and only few 
and questionable clinicians’ ratings. Compared with other studies, a possible shortcoming might 
lie in the fact that for pragmatic reasons, we chose to conduct only 25 training sessions since 
Arns et al., (2009) observed a correlation of the number of sessions with the reduction of inatten-
tion. More sessions and more transfer trials might have improved performance in those trials and 
clinical eﬀects might have become more robust. Further analysis of electrophysiological and neu-
ropsychological data and long-term outcome will help to understand the mechanisms underlying 
the reported speciﬁc and unspeciﬁc eﬀects. A major challenge for future studies will be to identi-
fy predictors to decide whether an individual patient would particularly beneﬁt from SCP-NF. 
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2.1.6 Supplementary Materials  
Table 8. Sensitivity Analysis: Differences in FBB-ADHS global score (Parents’ ratings; Post-
Test 2 minus Pretest between groups; PP Population; ANCOVA, BOCF) 
 Adjusted mean (95% CI) p-value 
EMG-Feedback -0.1074 ( (-0.2774 / 0.0626)  
Neurofeedback   -0.3287 (-0.4806 / -0.1769)  
Difference between treat-
ments 
   0.2213 (0.0293 / 0.4133)  
Treatment  0.0245 
FBB-ADHS global score  0.0042 
Gender  0.1199 
Trial site  0.9972 
Baseline ADHD medication 
(yes/no) 
 0.7604 
Parenting style  0.6001 
Parents’ expectations  0.9069 
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Table 9. Parents’ ADHD Ratings (mITT Population N=144) 
 NF EMG Total 
Pre-Test Post-Test 2 Pre-Test Post-Test 2 Pre-Test Post-Test 2 
Hyperactivity 
N 72 53 67 50 139 103 
Mean 
(SD) 
1.543 
(0.628) 
1.086 
(0.689) 
1.524 
(0.665) 
1.265 
(0.664) 
1.534 
(0.644) 
1.173 
(0.679) 
Missing 3 22 2 19 5 41 
Impulsivity 
N 72 53 67 50 139 103 
Mean 
(SD) 
1.927 
(0.690) 
1.453 
(0.574) 
1.799 
(0.779) 
1.685 
(0.779) 
1.865 
(0.734) 
1.566 
(0.688) 
Missing 3 22 2 19 5 41 
Inattention 
N 72 53 67 50 139 103 
Mean 
(SD) 
2.033 
(0.527) 
1.499 
(0·534) 
1.973 
(0.509) 
1.705 
(0.448) 
2.004 
(0.518) 
1.599 
(0.502) 
Missing 3 22 5 19 5 41 
Global Score* 
N 73 53 67 50 139 103 
Mean 
(SD) 
1.842 
(0.448) 
1.346 
(0.519) 
1.782 
(0.471) 
1.548 
(0.488) 
1.813 
(0.459) 
1.444 
(0.512) 
Missing 3 22 2 19 5 41 
*Global score could not be assessed if more than 2 items of subscales were missing 
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Table 10. Differences in FBB-ADHS global score (Teachers’ ratings; Post-Test 2 minus Pretest 
between groups; mITT population, ANCOVA, BOCF) 
 Adjusted mean (95% CI) p-value 
EMG-Feedback -0.1134 (-0.2628 / 0.0360)  
Neurofeedback -0.1549 (-0.2953 / -0.0145)  
Difference between treat-
ments 
0.0415 (-0.1240 /0.2070)  
Treatment  0.6204 
Baseline FBB-ADHS 
global score 
 <.0001 
Gender  0.9686 
Trial site  0.2200 
Baseline ADHD medica-
tion (yes/no) 
 0.8498 
Parenting style  0.6290 
Parents’ expectations  0.5949 
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Table 11. Teachers’ ADHD Ratings (mITT Population N=144) 
 NF EMG Total 
Pre-Test Post-Test 2 Pre-Test Post-Test 2 Pre-Test Post-Test 2 
Hyperactivity 
N 63 51 68 42 131 93 
Mean 
(SD) 
1.147 
(0.812) 
1.073 
(0.810) 
1.024 
(0.854) 
0.954 
(0.735) 
1.088 
(0.831) 
1.019 
(0.775) 
Missing 7 24 6 27 13 51 
Impulsivity 
N 68 51 63 42 131 93 
Mean 
(SD) 
1.412 
(0.954) 
1.270 
(0.963) 
1.310 
(0.954) 
1.298 
(0.926) 
1.363 
(0.952) 
1.282 
(0.941) 
Missing 7 24 6 27 13 51 
Inattention 
N 68 51 63 42 131 93 
Mean 
(SD) 
1.693 
(0·696) 
1.595 
(0.765) 
1.676 
(0.724) 
1.468 
(0.627) 
1.685 
(0.707) 
1.538 
(0.705) 
Missing 7 24 6 27 13 51 
Global Score* 
N 65 51 60 40 125 91 
Mean 
(SD) 
1.479 
(0.637) 
1.348 
(0.732) 
1.381 
(0.709) 
1.242 
(0.634) 
1.432 
(0.671) 
1.302 
(0.689) 
Missing 10 24 9 29 19 53 
* Global score could not be assessed if more than 2 items of subscales were missing 
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2.2 Study 2: Slow cortical potentials neurofeedback in children with ADHD: comor-
bidity, self-regulation and clinical outcomes six months after treatment in a mul-
ticenter randomized controlled trial  
 
 
 
 
 
 
 
 
_______________________ 
Published as: Aggensteiner, P.-M., Brandeis, D., Millenet, S., Hohmann, S., Ruckes, C., Beuth, S., 
Albrecht, B., … Holtmann, M. (2019). Slow cortical potentials neurofeedback in children 
with ADHD: comorbidity, self-regulation and clinical outcomes 6 months after treatment 
in a multicenter randomized controlled trial. European Child & Adolescent Psychiatry. 
https://doi.org/10.1007/s00787-018-01271-8 
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2.2.1 Abstract 
Despite sizeable short-term effects of neurofeedback (NF) therapy on attention-deficit and hyper-
activity disorder (ADHD), longer-term clinical, comorbidity and self-regulation outcomes are 
less systematically studied. The aim of this largest NF follow-up to date was to evaluate these 
outcomes six months after NF compared to a semi-active control to disentangle specific from 
unspecific sustained effects.  
We performed a multicentre, randomized, parallel, controlled, clinical, superiority trial in 
five German university outpatient departments. Participants were eligible if they fulfilled DSM-
IV-TR criteria for ADHD and were aged from 7 to 9 years. Participants were randomly assigned 
(1:1-ratio) to 25 sessions of slow-cortical potential (SCP)-NF or electromyogram biofeedback 
(EMG-BF). Participants were not blinded, since they received instructions according to each 
treatment setting. Primary outcome were parent ratings of ADHD. The trial was registered, num-
ber ISRCTN761871859.  
Both groups showed improvement of ADHD symptoms compared to baseline at six-months fol-
low-up with large effect sizes (ES) for SCP-NF (d=1.04) and EMG-feedback (d=0.85), but with-
out group differences. When analysing all assessments (pre-test, post-test-1, post-test-2 and fol-
low-up), a group-by-time interaction emerged (p=0.0062), with SCP-NF showing stable im-
provement following treatment but EMG-BF showing a relapse from post-test-1 to post-test- 2, 
and subsequent remission at follow-up.  
Six months after the end of treatment, improvement after SCP-NF remained large and stable. 
However, the lack of group differences at follow-up suggests shared specific and unspecific ef-
fects contributing to this clinical outcome. Our correlational results indicate specificity of SCP-
NF for selected subscales after training, but not at follow-up. 
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2.2.2 Introduction 
Attention-deficit/hyperactivity disorder (ADHD) is a common childhood psychiatric dis-
order with high worldwide prevalence of 2.6-4.5% (Polanczyk et al., 2015). It is considered a 
heterogeneous disorder, with a particularly high comorbidity rate of 40-70% with conduct prob-
lems (CP). Stimulant medication is the most common and effective treatment in severe ADHD, 
and about 70% of patients respond to this pharmacological approach (Spence et al., 1996). How-
ever, adverse events (Graham et al., 2011), unwillingness to take medication over extended peri-
ods (Berger et al., 2008), and particularly the absence of positive long-term effects (van de Loo-
Neus et al., 2011) are serious constraints of this treatment. Thus, there is a demand for alternative 
treatments with possible long-term effects such as Neurofeedback (NF), which aims to improve 
self-regulation of certain brain activity patterns (Sherlin et al., 2011). NF has gained encouraging 
empirical support in recent years. Meta-analysis on the effects of NF on ADHD symptoms 
showed medium to large effects for all three core domains of ADHD symptoms (Arns et al., 
2009). Although effects were substantially reduced for probably blinded raters in RCTs, NF ef-
fects remained significant in an exploratory analysis for studies using standard protocols (Cortese 
et al., 2016). Regarding sustained and long-term effects, a recent meta-analysis of ten studies 
(Doren et al., 2018) found small to medium effects for NF compared to non-active control condi-
tions at follow-up, and similar effects compared to active control conditions (pharmacotherapy 
and self-management). Moreover, the effects of NF treatment on CP and the role of this comor-
bidity on treatment response has not been widely studied in ADHD patients (Saylor & Amann, 
2016), although other behavioral ADHD treatments improve CP symptoms (Daley et al., 2014). 
Slow cortical potential (SCP)-NF focuses on regulating cortical activation and inhibition. 
These slow electrical shifts form a phasic mechanism in the regulation of attention (Rockstroh, 
Elbert, Lutzenberger, & Birbaumer, 1990). A well-studied SCP, the frontocentral contingent neg-
ative variation (CNV) reflecting cognitive activation and preparation, is reduced in ADHD chil-
dren compared with healthy controls (Albrecht et al., 2008). Promising effects of SCP-NF involv-
ing upregulation of CNV-like negative SCPs on ADHD have been reported in several studies 
(Drechsler et al., 2007; Gevensleben et al., 2009; Holtmann et al., 2004; Strehl et al., 2006; Strehl 
et al., 2017). 
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The few studies investigating impact of NF on comorbid CP generally found positive ef-
fects on CP symptoms. Gevensleben and colleagues (Gevensleben et al., 2009) assessed signifi-
cant reductions on parent-rated oppositional behavior (ODD) and CP compared to standardized 
computerized attention training. After theta/beta NF training, reduction of ODD symptoms were 
reported but without a group difference when compared with standard pharmacological interven-
tion (Meisel et al., 2013). Furthermore, one study investigated SCP-NF in criminal psychopaths 
showing less aggression and impulsivity (Konicar et al., 2015). 
A key question in NF is whether the ability to learn and self-regulate unconscious psy-
chophysiological parameters relates to clinical outcomes and thereby supports the specificity of 
treatment effects. Two studies (Drechsler et al., 2007; Strehl et al., 2006) linked self-regulation 
outcome with impulsivity, inattention and hyperactivity subscales when participants were classi-
fied as learners. Gevensleben and colleagues (2009) reported that successful initial increases of 
negativity (until the ninth session) correlated with inattention improvement. However, one recent 
frequency band NF study (Janssen et al., 2016) could not find any association between self-
regulation and symptom reduction. These analyses are important to disentangle specific from 
unspecific effects provided by NF treatment approaches.  
The relation between long-term effects and self-regulation in ADHD participants was ana-
lyzed only in one study six months after SCP-NF treatment. Strehl (2006) reported medium to 
large effect sizes, which were predicted by self-regulation performance during transfer conditions 
after training, and as a trend at follow-up.  
The main aim of this follow-up on our large randomized controlled multicenter trial, 
which demonstrated a superior primary ADHD outcome for SCP-NF compared to a semi-active 
control group (Strehl & Aggensteiner et al., 2017), was to evaluate the clinical long-lasting ef-
fects on ADHD and CP symptoms and relate them to self-regulation capabilities.   
2.2.3 Materials and Methods  
2.2.3.1 Study design and participants 
We did a multicenter, randomized controlled, parallel, superiority trial. The study was ap-
proved by all local ethics committees according to the Declaration of Helsinki. Written consent 
was obtained from all participants and their persons in charge of primary custody. For more de-
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tails see (Holtmann et al., 2014)  regarding the study protocol and randomization and (Strehl & 
Aggensteiner et al., 2017) regarding the primary outcomes 4 weeks after treatment. Participants 
had to meet the diagnosis of ADHD combined type according to DSM-IV TR and aged 7 to 9 
years. Comorbid symptoms at baseline were assessed by the Child behavior Checklist (CBCL). 
Exclusion criteria consisted of a diagnosis of bipolar disorder, psychosis, obsessive-compulsive 
disorder, chronic severe tics or Tourette syndrome, major neurological or physical illness, acute 
suicidal tendencies, pharmacotherapy for severe anxiety, mood disorders and psychosis, IQ be-
low 80, lack of German-language proficiency, no telephone, pregnancy and lactation, and current 
participation in other clinical trials. Since the interventions were considered an add-on to treat-
ment as usual, pharmacotherapy for ADHD, ODD and CD was allowed.  
2.2.3.2 Procedures 
After screening, there was a washout period of 2 weeks for children with psychostimu-
lants and 4 weeks for participants with atomoxetine. Assessments were carried out at pre-
intervention (pre-test), after treatment (post-test 1), one-month after treatment (post-test 2) and 
six months later (follow-up). Pre-tests and post-tests 2 were conducted without medication, and 
six months after treatment end participants underwent a naturalistic follow-up. Participants were 
trained one to two times per week for a total of 25 sessions within three months. Six months after 
training, a follow-up and booster session probed the sustainability of acquired self-regulation 
skills. Each session lasted about one hour. 
SCP-NF sessions were conducted with NEUROPRAX systems (neuroCare GmbH, Ger-
many) using a monopolar setting (Cz, referenced to the right mastoid).  Each training session 
consisted of three feedback runs (with visual feedback) and one transfer run (without feedback). 
A run consisted of 40 trials, each lasting 10 s, with three phases (2 s baseline and 8 s feedback, 
followed by a “sun” for reinforcement after successful trials). The participants had to differentiate 
between activation and deactivation of brain activity. During an “activation”-task an electrically 
negative SCP shift was required, in contrast to the “deactivation”-task, asking for an electrically 
positive shift. The baseline was set to zero. Trials were randomly distributed with a 50/50% rate 
for the first phase of the training (Sessions 1-12). Thereafter, participants had a 3-4 weeks break. 
The second phase of the training (Sessions 13-25) was more focused on “activation” with 80% 
negative SCP-shifts.  
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The semi-active control condition EMG-BF required coordinated activity of the suprasp-
inate muscles. Participants were instructed either to contract or to relax the left in relation to the 
right supraspinate muscle. Setting, training devices, electrode montage, feedback and transfer 
trials, number of sessions, and follow-up assessments were the same as in the SCP-NF group. 
2.2.3.3 Outcomes 
The primary outcome was ADHD symptoms rated by parents. The secondary outcomes 
were teacher-rated ADHD scale, time course of Comorbid symptoms which were rated by par-
ents via the Strengths and Difficulties Questionnaire (SDQ) and NF training self-regulation per-
formance (percentage of correct trials) and its relation to clinical outcomes. Psychometric proper-
ties of all pre-specified measures are reported in the protocol (Holtmann et al., 2014). 
 
2.2.3.4 Statistical analysis 
Statistical analyses were run using the Statistical Package for Social Sciences version 23.0 
(SPSS). Post-intervention (post-test 2) effects have been reported previously (Strehl & Aggen-
steiner et al., 2017). This study evaluated sustained and long-term effects between treatments. 
Primary outcomes (ADHD parent ratings) were tested by an analysis of covariance (ANCOVA) 
to test sustainability of effects (Follow-up minus post-test 2), as predefined in our protocol 
(Holtmann et al., 2014) and the longitudinal course across all assessments was analyzed using a 
mixed model for repeated measure (MMRM). ANCOVA analysis included the covariates trial 
site, sex, age, baseline ADHD score, ADHD medication at pre-test, parenting style and parents´ 
expectations. The MMRM model included fixed effects for group, site, time and group by time 
interaction, adding sex, age, baseline ADHD score, ADHD medication at pre-test, parenting style 
and parents´ expectations as covariates. We also repeated the same MMRM analysis substituting 
medication status at pre-test with medication at follow-up.  
Secondary outcomes (ADHD teacher ratings) were tested by an analysis of covariance 
(ANCOVA) with trial site, sex, age, baseline ADHD score, ADHD medication at pre-test, parent-
ing style and parents´ expectations as covariates. Differences were calculated between follow-up 
and post-test 2 assessments to test sustained effects and between follow-up and pre-test to test 
long-term clinical effects. Paired T-Tests were used for within group analysis. Between-treatment 
Empirical studies 
 
60 
effect sizes were calculated by dividing the treatment-group differences by the pooled standard 
deviation at pre-test. Within-treatment effect sizes were calculated by dividing the mean of 
changes by the standard deviation at pre-test. Influence of baseline comorbid CP on the primary 
outcome was assessed repeating the main analysis introducing conduct problems as an additional 
covariate. The course of comorbid conduct problems and other comorbid symptoms over time 
was assessed via the SDQ measuring CP, emotional problems, and peer problems in addition to 
total problems and hyperactivity. Non-parametric Wilcoxon signed rank tests were used for this 
statistical analysis. NF self-regulation was analyzed based on the regression slope of all selected 
mean training sessions (for details see Strehl & Aggensteiner et al., 2017). Consolidation of per-
formance was compared by paired T-test between follow-up training session and the first mean 
session using online obtained reinforcement rate. Pearson’s or spearman correlations were as-
sessed to link linear regression of self-regulation performance and clinical outcome for ADHD 
and comorbid symptoms.  
For the ANCOVA data were analyzed primarily in the modified intention-to-treat (mITT) 
population, comprising all patients except those who received no treatment due to violation of 
inclusion criteria. Baseline observation carried forward (BOCF) was used to replace missing val-
ues for analysis of covariance.  
2.2.4 Results 
A total of 174 participants were recruited between September 2009 and January 2013 for 
screening, 150 (86%) of whom were allocated to one of the two treatment groups and 144 (82%) 
participants started the treatment. The CONSORT ﬂow diagram is depicted in Figure 8. Finally, 
the mITT population comprised 75 (52%) participants in SCP-NF and 69 (48%) in EMG-BF. In 
SCP-NF 60 (41%) and in EMG 51 (35%) participants completed treatment and took part in all 
assessment points. Baseline characteristics did not differ between groups and are depicted in Ta-
ble 12. 
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Figure 8. Trial profile. Modified from Strehl et al., (2017). SCP-NF slow cortical potential neu-
rofeedback, EMG-BF electromyographic biofeedback, mITT modified intention to treat. 
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Table 12. Baseline characteristics of the mITT population 
 
As predefined in our protocol, we performed an ANCOVA assessing the sustained effects 
between groups (follow-up minus post-test 2) of the ADHD global score rated by parents re-
vealed a trend for a superior improvement after EMG-BF versus SCP-NF (BOCF: treatment dif-
ference: 0.15, p=0.066, ES 0.32), while no effect of sex, trial site, medication, symptom severity 
at baseline, parenting style, parents´ expectation, and age was observed. Regarding ADHD sub-
domains, ANCOVA yielded significant group differences for hyperactivity only (BOCF: treat-
ment difference: 0.19, p=0.013, ES 0.44). No effect of sex, trial site, medication, parenting style 
and parents´ expectation was observed, but age (p=0.044) showed a positive association with 
improved hyperactivity (Supplementary Table 15). 
Analyzing the longitudinal course across all assessments from pre-test to end of six 
months follow-up together using the MMRM showed large within group improvement on the 
ADHD global score for both treatments (time difference: 0.43, p<0.0001) with significant group-
by-time interaction [F(3,4.376), p=0.006]. Figure 9 shows the clinical trajectories for all assess-
 SCP-NF n=75  EMG-BF n=69   
 Mean (SD) Mean (SD) 
Age  (years) 8.6 (0.92) 8.57 (0.88) 
Female 
Male 
14 (18.67%) 
61 (81.33%) 
11 (15.94%) 
58 (84.06%) 
ADHD global score 1.842  0.448  1.782  0.471 
ADHD medication prior to study 34 (45%) 27 (39.1%) 
CBCL t-value 
Global 
Externalizing problems 
Internalizing problems 
 
63.6 (8.4) 
66.3 (9.4) 
62.2 (9.5) 
 
63.2 (7.8) 
64.8 (9.4) 
62.4 (9.3) 
SDQ total score 17.49 (6.0) 17.69 (5.5) 
CPM (percentage rank) 
equivalent IQ value 
63.4 (27.0) 
105 
65.5 (27.0) 
106 
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ments for primary outcome rated by parents and in Table 13 results of the MMRM are depicted. 
Both groups showed large initial improvement immediately after 25 training sessions (post-test 
1). However, one month after treatment,  following the medication washout, only the SCP-NF 
group remained stable and the EMG-BF group showed a significant relapse, resulting in signifi-
cant group differences (group difference: -0.21, p=0.019). However, at follow-up assessment 
group differences disappeared (group difference: -0.065, p=0.534), indicating that the EMG-BF 
group significantly recovered (improved) from post-test 2 to follow-up assessment (time differ-
ence: 0.16, p=0.035). Regarding the covariates, age (p=0.008), and symptom severity at baseline 
(p<0.0001) showed significant impact on treatment outcome, reflecting more improvement with 
increasing age or more severe baseline ADHD (Supplementary Table 16). Further, when repeat-
ing the same analysis with medication status at follow-up, a significant interaction for time-by-
medication [F(3,2.858), p=0.045], but not for time-by-group-by-medication [F(3,0.365), 
p=0.778] emerged (Supplementary Table 17). The post-hoc tests indicated that only medicated 
participants showed a significant recovery from post-test 2 to follow-up (time difference: 0.16, 
p=0.048), while unmedicated participants showed a stable improvement after post-test 1. 
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Table 13. Summary of primary outcome: ADHD FBB-HKS rated by parents 
  
Assessment 
GROUP         Long-term effect size  
 
NFB EMG Group differences Between groups Within groups
a
 
 Mean 
95% CI 
Mean 
95% CI 
 
95% CI   
ES 
ES 
 
        Difference     p SCP-NF EMG-BF 
G
lo
b
al
 s
ca
le
 Pre-test 1.79 1.79 1.79 1.79 1.79 1.79 0.00 0.00 0.00 0.8760 
   Post-test 1 1.37 1.22 1.51 1.41 1.25 1.56 -0.04 -0.23 0.17 0.7190 0.08 0.97*** 0.86*** 
Post-test 2 1.34 1.20 1.47 1.55 1.41 1.69 -0.21 -0.40 -0.04 0.0288* 0.57* 1.09*** 0.48** 
Follow-up 1.33 1.18 1.49 1.38 1.22 1.54 -0.04 -0.27 0.14 0.6954 0.05 1.04*** 0.85*** 
        
 
     
 
In
at
te
n
ti
o
n
 Pre-test 2.03 1.94 2.12 1.98 1.87 2.05 0.05 -0.09 0.16 0.3111 
  
 
Post-test 1 1.52 1.39 1.65 1.56 1.40 1.68 -0.04 -0.20 0.17 0.8053 0.16 0.91*** 0.87*** 
Post-test 2 1.51 1.38 1.63 1.71 1.57 1.82 -0.20 -0.36 -0.01 0.0348* 0.54* 1.03*** 0.52** 
Follow-up 1.53 1.38 1.67 1.60 1.43 1.73 -0.07 -0.27 0.15 0.6321 0.20 1.00*** 0.66*** 
               
H
y
p
er
ac
ti
v
it
y
 Pre-test 1.47 1.38 1.56 1.53 1.44 1.62 -0.05 -0.19 0.73 0.3950 
  
 
Post-test 1 1.16 0.99 1.32 1.10 0.92 1.28 0.06 -0.19 0.31 0.6320 -0.16 0.57** 0.71*** 
Post-test 2 1.09 0.94 1.24 1.27 1.10 1.43 -0.18 -0.40 0.05 0.0866°  0.27° 0.70*** 0.4** 
Follow-up 1.12 0.96 1.29 1.05 0.87 1.22 0.08 -0.17 0.31 0.5446 -0.20 0.61** 0.80*** 
Im
p
u
ls
iv
it
y
 Pre-test 1.89 1.75 2.02 1.81 1.68 1.95 0.07 -0.12 0.26 0.4566 
  
 
Post-test 1 1.54 1.38 1.71 1.63 1.45 1.81 -0.09 -0.33 0.16 0.4829 0.27 0.55*** 0.25 
Post-test 2 1.49 1.32 1.66 1.69 1.51 1.87 -0.20 -0.44 0.05 0.1153 0.50 0.64*** 0.16 
Follow-up 1.48 1.32 1.65 1.58 1.40 1.76 -0.10 -0.15 0.34 0.4341 0.22 0.64*** 0.38* 
Note: Adjusted means. MMRM= Mixed model repeated measure. Bonferroni adjustment for multiple comparisons. 
a
Effect sizes for follow-up, post-test 2 and post-
test 1 minus pre-tests.°p < 0.1 *p < 0.05 **p < 0.01 ***p < 0.001. 
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In exploratory additional medication subgroup analyses, the group by time interaction re-
mained significant for parent ratings in consistently unmedicated patients [N= 25 vs 24; 
F(3,2.122), p=0.025]. Analysis of the consistently medicated participants showed a significant 
group effect for the impulsivity subscale [n= 21 vs 19; F(1,8.020), p=0.007]. Post-hoc analysis 
revealed significant lower impulsivity for the SCP-NF group for post-test 1 (p=.054), post-test 2 
(p=.003) and follow-up (p=.008). Changes in medication status during the study were comparable 
in both groups (see Supplementary Table 18). There was no evidence that more children reduced 
medication use in the SCP group (n=4) than in the EMG (n=7).  
ADHD subscales rated by parents are depicted in Figure 9. Similar results as in the prima-
ry outcome were obtained. Inattention [F(3,110.26)= 27.753, p<0.0001] and hyperactivity 
[F(3,107.28)= 18.316, p<0.0001] achieved a significant effect of time. Hyperactivity subscale 
showed significant group-by-time interaction [F(3,107.24)=3.476, p=0.018] and inattention a 
trend [F(3,110.23)= 2.506, p=0.062]. The impulsivity subscale showed as well a significant effect 
of time [F(3,111.03)=10.767, p<0.0001], however without a group-by-time interaction 
[F(3,111.00)=1.724, p=0.1661].  
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Figure 9. Clinical trajectories of ADHD parent ratings. Pre-test and post-test 2 were conducted 
without medication. °p<0.1, *p<0.05 
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ANCOVA between groups assessing the secondary outcome rated by teachers did not 
show any significant difference between groups neither for sustained effects (follow-up minus 
post-test 2; BOCF: treatment difference: -0.09, p=0.3559) nor for long-term effects (follow-up 
minus pre-tests; BOCF: treatment difference: -0.15, p=0.1480) (for details see Supplementary 
Table 19). Within group analysis are depicted in Table 14. SCP-NF showed significant improve-
ment for ADHD global score t(64)=3.055 p=0.0032 and all subdomains for long-term effects 
with small to medium effect sizes. For EMG-BF teacher ratings showed only a trend improve-
ment for the impulsivity subdomain t(62)=1.807, p=0.0756.  
 
Table 14. Summary of secondary outcomes: ADHD rating scale rated by teachers (mITT popula-
tion, N= 144, BOCF). 
 
Pre-tests 
  
  
Post-test 2 
 
    
Follow-up 
 
 
 
 
  
Follow-up  
minus Pre-test 
a
 
Follow-up  
minus Post-test 2 
a
 
              SCP-NF Mean n SD Mean n SD Mean n SD ES p ES p 
Global score* 1.48 65 0.64 1.34 69 0.69 1.28 65 0.66 0.34 0.003** 0.09 0.61 
Inattention 1.69 68 0.70 1.60 70 0.69 1.52 68 0.68 0.24 0.015* 0.07 0.68 
Hyperactivity 1.15 68 0.81 1.05 70 0.79 0.95 68 0.79 0.25 0.033* 0.13 0.43 
Impulsivity 1.41 68 0.95 1.23 70 0.93 1.20 68 0.89 0.23 0.012* 0.04 0.82 
EMG-BF                           
Global score* 1.38 60 0.71 1.32 61 0.65 1.30 60 0.68 0.12 0.205 0.00 0.98 
Inattention 1.68 63 0.72 1.60 64 0.68 1.58 63 0.71 0.13 0.230 0.00 1.00 
Hyperactivity 1.02 63 0.85 0.99 64 0.77 0.99 63 0.78 0.04 0.557 -0.03 0.82 
Impulsivity 1.31 63 0.95 1.26 64 0.90 1.20 63 0.90 0.13 0.075 0.05 0.56 
Note: ∗ Global score could not be assessed if more than two items in subscales were missing. a Within 
group analysis. *p<.05 **p<.01 ***p<.001. 
 
To assess long-term effects of learning on self-regulation we grouped participants into 
learners and non-learners based on the sign of their regression slope over sessions including the 
follow-up session for the feedback and transfer condition separately. For SCP-NF 63.5% of the 
participants were classified as learners for the feedback condition and 58.3% for the transfer con-
dition. In the semi-active control group, 70.2% were classified as learners during the feedback 
condition and 80.7% for the transfer condition. Paired T-Tests for showed significant improve-
ment of performance only during transfer trials between follow-up sessions and first training ses-
sions for SCP-NF (t(42)=2.438, p=0.019) and EMG-BF (t(38)=4.650, p<0.0001). For details see 
Supplementary Figure 11. 
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Long-term clinical effects (follow-up minus pre) and self-regulation performance did not 
show any significant correlation for SCP-NF. For the semi-active control group we found signifi-
cant correlations between linear performance increase and parent rating scale for ADHD global 
score (r(48)=0.361, p=0.011), inattention (r(48)=0.302, p=0.0370), and hyperactivity 
(r(48)=0.367, p=0.010) but no significant correlation with teacher ratings. As reported in our pre-
vious study (Strehl & Aggensteiner et al., 2017), no significant correlations between training per-
formance and parent-rated ADHD global score were found at post-test 2. However, the analysis 
of ADHD core symptom subdomains revealed a significant correlation of improvement of per-
formance until post-test 2 for SCP-NF with parent (r(41)=0.401, p<0.009) and teacher ratings 
(r(36)=0.339, p=0.043) for improvement of impulsivity and a trend for hyperactivity 
(r(41)=0.256, p<0.0976) rated by parents´. In the EMG-FB group, parent-rated hyperactivity cor-
related significantly negative (r(41)= -0.391, p=0.036) with improved performance. For details 
see Supplementary Table 20.  
Conduct problems at baseline did not significantly impact the clinical ADHD symptom 
change at follow-up on the FBB global scale (p=0.576) or any subdomain rated by parents´ and 
teachers´ (all p>0.1844). Regarding the clinical effects on comorbidity measured by the SDQ, 
Wilcoxon signed rank test showed significant improvement at follow-up compared to pre-test 
rated by parents for SDQ total score (U=922.0, z= -5.337,p<0.0001), and the subdomain conduct 
problems (U=843.5, z= 3.792,p<0.0001), with no significant group differences. The other SDQ 
subdomains also improved (hyperactivity U=471.0, z= -5.727,p<0.0001, emotional problems, 
(U=471.0, z= 5.727,p<0.0001) and peer problems (U=1.012, z= 3.642,p<0.0001) except proso-
cial behavior (U=1.474, z= -1.062, p=0.288). Significant group differences emerged only for the 
subdomain peer-problems (in favor of SCP-NF: U=1833.5, z= 2.617, p=0.009). Significant corre-
lations between self-regulation during the transfer condition and symptom reduction were found 
only in the SCP-NF group, and only for SDQ total score (rs(58)= -0.285, p=0.030), peer problems 
(rs(58)= -.349, p=0.007) and at trend level for CP (rs(58)= -0.255, p=0.052) and hyperactivity 
(rs(58)= -0.247, p=0.061). 
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2.2.5 Discussion 
We studied the long-term effects of SCP-NF compared to a semi-active control condition. 
Our study showed that both treatments showed large improvements on ADHD core symptoms 
direct after treatment. Superior results for SCP-NF one month after treatment end, became non-
significant at follow-up for the primary outcome rated by parents. However, the improvements 
seen at post-test 1 remained stable six months after treatment end for the SCP-NF, suggesting 
long-lasting effects. Interestingly, the semi-active control group showed a significant relapse dur-
ing the medication washout from post-test 1 to post-test 2 with a significant recovery at follow-
up, suggesting that these changes are driven by a medication effect. This finding might resemble 
the observation of Monastra and colleagues (Monastra, Monastra, & George, 2002), where only 
the control group deteriorated after medication washout. However, in our study, medication did 
not show such group-specific effects, and the significant time-by-medication interaction at fol-
low-up did not interact with group. Since the clinical trajectories suggested that the medicated 
SCP-NF subgroup improved more, we also performed subgroup analyses of consistently medi-
cated and unmedicated participants. However, these revealed no new NF-specific improvements, 
and did not change the finding with the entire sample.  Nevertheless, age did significantly impact 
treatment outcome, suggesting that the long term effect of these intense treatments may benefit 
from the common symptom reduction with development (Biederman, Mick, & Faraone, 2000).  
Also, baseline severity remained significantly associated with improvement at follow-up, which 
may reflect continued regression to the mean or more room for improvement. 
Regarding the clinical effects after SCP-NF, our results are in line with a recent meta-
analysis (Doren et al., 2018), which analyzed sustained effects after NF in comparison with active 
and non-active control groups. This meta-analysis showed that superior clinical effects at follow-
up for NF only holds true when it was compared with non-active control groups and showed sim-
ilar effects compared with active conditions. Our study used a semi-active control group which 
might be considered as a more rigorous control condition compared to non-active control groups. 
This, together with the developmental effects and the possible influence of additional confound-
ers, may explain the missing superiority of SCP-NF six months after treatment. A recent study 
from Geladé and colleagues (Geladé et al., 2017) showed that a significant advantage of medica-
tion over NF seen at post intervention disappeared at FU. These findings suggest that in other 
study designs, NF-specific improvements may appear only at FU. Concerning teacher ratings, no 
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differences between groups were found. However, within group analysis showed significant im-
provement in the SCP-NF group only, with small to medium effect sizes. Teachers may be less 
biased but also tend to be less sensitive (Minder, Zuberer, Brandeis, & Drechsler, 2018), although 
in a recent follow-up study (Geladé et al., 2017) teacher ratings indicated an advantage of NF 
over a non-active group, comparable to medication. Further, reductions of comorbidity symptoms 
measured by SDQ were significant and independent of groups, except for peer problems which 
improved more in the SCP-NF group.  
Considering the association between self-regulation and clinical outcome, only very few 
SCP-NF studies followed this relationship in participants with ADHD after the end of NF treat-
ment (Drechsler et al., 2007; Strehl et al., 2006). They related self-regulation outcome to impul-
sivity, inattention and hyperactivity at the end of treatment. We reported significant correlations 
between clinical improvement and self-regulation performance for both groups. The SCP-NF 
group showed at post-test 2 a significant correlation with self-regulation and symptom improve-
ment for impulsivity and a trend for hyperactivity rated by parents and teachers, whereas the 
EMG-BF group showed a significant negative correlation for self-regulation and hyperactivity 
only. These outcomes might be interpreted as a specific effect of SCP-NF. However, at the fol-
low-up six months after treatment, the EMG-BF group showed significant correlations between 
self-regulation performance and ADHD global score, attention and hyperactivity subdomain, 
which might be due to unspecific effects, such as the developmental course or regression to the 
mean. Interestingly, symptom change measured with SDQ at follow-up showed specific correla-
tions between self-regulation and symptom improvement only for the SCP-NF group. Overall, 
after these unexpected and mixed outcomes, no firm conclusions can be drawn regarding specific 
and unspecific effects related to self-regulation for the follow-up outcomes after NF. 
As limitation we may consider that our follow-up was not powered enough to disentangle 
specific from unspecific effects between groups six months after treatment. Additionally, our 
SCP-NF setup could be insufficient regarding the trained parameters (i.e. compared to other stud-
ies fewer training and particularly transfer trials) as well as the overall regulation performance 
during SCP-NF training. Our participants achieved a mean reinforcement rate of 44% for SCP-
NF and 82% for EMG-BF. Still, these data are in line with the few published studies. Some SCP-
NF studies (Baumeister et al., 2016; J. Takahashi, Yasumura, Nakagawa, & Inagaki, 2014) 
showed reinforcement rates around 40% or less, and similar good performance for the EMG-BF 
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(Baumeister et al., 2016; Maurizio et al., 2013), indicating as expected that EMG-regulation is 
easier to learn. The rather low regulation (percentage of correct trials) of SCP-NF might be an 
important factor and potentially explain the absence of group differences at follow-up for the 
primary outcome and teacher ratings, as well as the modest relationship between self-regulation 
and clinical improvement. Self-regulation is known as an important unspecific variable contrib-
uting to the clinical outcome in biofeedback treatments. Therefore, the substantial lower reward 
rates for SCP-NF compared to EMG-BF as in this study may have interfered with the specific 
effects. Future studies should ensure enough learning and address the question why participants 
do show low regulation performance.  
In conclusion, the superiority of SCP-NF over the semi-active control group, which was 
reported in our previous paper, became non-significant six months after treatment end but only 
the semi-active control group showed a relapse one month after treatment. This study adds im-
portant outcomes regarding the specificity of SCP-NF and the possible influence of unspecific 
variables on long-term treatment outcome.  
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2.2.6 Supplementary Materials  
Table 15. Parent ratings (Hyperactivity); Follow-up minus Post 2 between groups; mITT. BOCF; 
ANCOVA. df=degree(s) of freedom 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Adjusted mean (95% CI) p F df 
EMG-BF -0.169 (-0.279/-0.059) 
 
  
 
SCP-NF 0.027(-0.079 / 0.134) 
 
  
 
Difference between treatments 0.197 (-0.352 / -0.042) 
 
  
 
Treatment   0.013 6.302 1 
Baseline ADHD global score   0.238 1.406 1 
Sex   0.229 1.460 1 
Trial site   0.484 0.494 4 
Age   0.044 4.136 1 
ADHD medication at PRE 
(yes/no)  
  0.953 0.004 1 
Parenting style (mean)   0.886 0.021 1 
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Table 16. Type III Tests of Fixed Effects
a
 
 
Source 
Numerator 
df Denominator df F Sig. 
Intercept 1 182.95 70.25 <0.0001 
Group 1 182.91 1.12 0.291 
Time 3 73.01 24.26 <0.0001 
Group * Time 3 73.05 4.20 0.0084 
Site 4 182.87 1.28 0.279 
Age 1 194.89 6.97 0.0089 
Parents´expectation 1 173.73 1.16 0.283 
Parenting style 1 186.51 0.23 0.633 
Gender 1 174.30 3.35 0.069 
Medication at Pre 
Yes/No 
1 184.57 0.00 0.961 
Bseline ADHD global 
score 
1 187.22 135.47 <0.0001 
a. Dependent Variable: ADHD global score 
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Table 17. Type III Tests of Fixed Effects
a
 
 
Source Numerator df 
Denominator 
df F Sig. 
Intercept 1 196.281 8.521 0.0046 
Group 1 197.030 0.782 0.378 
Time 3 58.773 6.257 0.001 
Medication at follow-up Yes/No 1 196.981 0.120 0.730 
Site 4 149.677 1.811 0.130 
Bseline ADHD global score 1 148.437 692.502 <0.0001 
Age 1 148.972 13.166 <0.0001 
ErwartungenderElternMittelwert 1 148.421 3.390 0.068 
Parenting style 1 148.650 0.000 0.9898 
Gender 1 147.457 3.490 0.064 
Group * Time 3 59.313 4.554 0.006 
Group * Medication at follow-
up 
1 149.740 0.048 0.826 
Time * Medication at follow-up 3 59.262 2.801 0.048 
Group * Time * Medication at 
follow-up 
3 58.135 0.324 0.808 
a. Dependent Variable: ADHD global score 
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Figure 10. ADHD Global score rated by parents. Significant interaction for time-by-medication 
(F(3.2.858), p=0.0453), but not for time-by-group-by-medication (F(3.0.365), p=0.7785) 
emerged. The post hoc tests indicated that only medicated participants showed a significant re-
covery from post-test 2 to follow-up (time difference: 0.16 95% CI -0.321 to -0.001, p=0.0482), 
while unmedicated participants showed a stable improvement after post-test 1. 
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Table 18. Medicated participants at each assessment point 
 
      
 
SCP-NF EMG-BF 
 
Statistics 
 
Yes No Yes 
N
   No 
  Pre 34 39 28 41 1 
 
 
46.6% 53.4% 
 
40.6% 59.4% 
 
X
2
 
p=.502 
Post 1 27 39 23     34 1 
 
 
40.9% 59.1% 34.8% 
 
51.5% 
 
X
2
 
p=1.00 
Post 2 28 34             23      32 1 
 
 
45.2% 54.8% 37.1% 51.6% 
 
X
2
 
p=.712 
FU 27 27 22      26 1 
 
 
50.0% 50.0% 40.7% 48.1% 
 
X
2
 
p=.694 
       Medication change On Off On Off     
On/off Pre - Post 1 1 2 2 1 
  
 
1.4% 2.7% 2.9% 1.4% 
  On/off Pre - Post 2 4 2 4 3 
  
 
5.5% 2.7% 5.8% 4.3% 
  On/off Pre to FU 5 0 4 3 
  
 
6.8% 0.0% 5.8% 4.3% 
  
       Total 10 4 10 7 
              
Note: Proportion of medicated participants at each time point where data was available. 
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Table 19. Teacher ratings; Global score: Follow-up minus Post 2 between groups; mITT. BOCF; 
ANCOVA. df=degree(s) of freedom 
 
 
 
 
 
 
 
 
 
 
 
  Adjusted mean (95% CI) p F df 
EMG 0.058 (-0.088/0.203) 
   
SCP-NF -0.032 (-0.168 / 0.104) 
   
Difference between treatments -0.090 (-0.282 / 0.102) 
   
Treatment 
 
0.3559 0.859 1 
Baseline ADHD global score 
 
0.3470 0.892 1 
Sex 
 
0.2177 1.536 1 
Trial site 
 
0.4931 0.855 4 
Age 
 
0.6428 0.0216 1 
ADHD medication at PRE 
(yes/no)  
  0.8565 0.033 1 
Parenting style (mean)   0.9916 0.000 1 
Parents’ expectations (mean)   0.1430 2.175 1 
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Figure 11. Self-regulation performance 
Data partly published in Strehl et al., 2017. ***p<.001 **p<.01 *p<.05. 
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Table 20. Correlation matrix. Performance and clinical change. Follow-up minus Pre 
       Parent ratings (Follow-up minus Pre) Teacher ratings (Follow-up minus Pre) 
GROUP 
FBB 
Global 
scale 
FBB Inatten-
tion 
FBB Hyperac-
tivity 
FBB Impul-
sivity 
FBB 
Global 
scale 
FBB Inatten-
tion 
FBB Hyperac-
tivity 
FBB Impul-
sivity 
S
SCP-NF 
F
FB 
Pearson 
Correlation 
0.112 -0.008 0.137 0.207 0.104 -0.016 0.206 0.065 
Sig. (2-tailed) 0.4236 0.9545 0.3285 0.1371 0.5249 0.9218 0.2017 0.6887 
N        53 53 53 53 40 40 40 40 
T
TF 
Pearson 
Correlation 
0.029 -0.067 0.080 0.090 -0.003 0.176 -0.020 -0.290 
Sig. (2-tailed) 0.8394 0.6357 0.5673 0.5223 0.9862 0.2771 0.9022 0.0698 
N         53 53 53 53 40 40 40 40 
F
FB + 
TF 
Pearson 
Correlation 
0.083 -0.045 0.128 0.175 0.056 0.104 0.102 -0.149 
Sig. 
(2-tailed) 
0.5546 0.7515 0.3592 0.2092 0.7320 0.5244 0.5307 0.3594 
N        53 53 53 53 40 40 40 40 
E
EMG-
BF 
F
FB 
Pearson 
Correlation 
0.361* 0.302* 0.367* 0.260 0.170 0.301 -0.025 0.056 
Sig. (2-tailed) 0.0117 0.0371 0.0104 0.0740 0.3683 0.1057 0.8973 0.7684 
N        48 48 48 48 30 30 30 30 
T
TF 
Pearson 
Correlation 
-0.246 -0.172 -0.257 -0.234 -0.152 -0.209 -0.101 -0.011 
Sig. (2-tailed) 0.0913 0.2414 0.0774 0.1088 0.4220 0.2666 0.5946 0.9546 
N 48 48 48 48 30 30 30 30 
F
FB + 
TF 
Pearson 
Correlation 
-0.031 0.003 -0.037 -0.070 -0.033 -0.006 -0.101 0.023 
Sig. (2-tailed) 0.8365 0.9835 0.8027 0.6357 0.8641 0.9729 0.5964 0.9045 
N 48 48 48 48 30 30 30 30 
 
Note: FB=Slope of feedback run. TF=Slope of transfer run. FB+TF=Mean slope of FB & TF. **p<.01.*p<.05. °p<.01 
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Correlation matrix. Performance and clinical change. Post-test 2 minus Pre 
   
Parent ratings (Post-test 2 minus Pre) Teacher ratings (Post-test 2 minus Pre) 
GROUP 
FBB 
Global 
scale 
FBB Inatten-
tion 
FBB Hyperac-
tivity 
FBB Impul-
sivity 
FBB 
Global 
scale 
FBB Inatten-
tion 
FBB Hyperac-
tivity 
FBB Impul-
sivity 
S
SCP-NF 
F
BF 
Pearson 
Correlation 
0.144 -0.055 0.256 0.256 -0.084 -0.024 0.024 0.199 
Sig. (2-tailed) 0.356 0.728 0.097 0.098 0.630 0.890 0.891 0.246 
N 41 41 41 41 35 36 36 36 
T
TF 
Pearson 
Correlation 
0.196 -0.016 0.257 .401** -0.002 -0.013 0.009 -0.102 
Sig. (2-tailed) 0.218 0.919 0.105 0.009 0.990 0.940 0.960 0.561 
N 41 41 41 41 35 36 36 36 
F
FB + 
TF 
Pearson 
Correlation 
0.090 -0.034 0.155 0.171 -0.140 0.095 -0.023 .339* 
Sig. (2-tailed) 0.567 0.828 0.320 0.274 0.421 0.582 0.895 0.043 
N 41 41 41 41 35 36 36 36 
EMG-
BF 
F
FB 
Pearson  
Correlation 
-0.066 0.087 -0.140 -0.153 -0.167 0.248 0.027 0.132 
Sig. (2-tailed) 0.703 0.614 0.417 0.373 0.378 0.178 0.885 0.481 
N 36 36 36 36 31 31 31 31 
T
TF 
Pearson 
Correlation 
0.178 0.211 0.231 -0.135 0.043 0.137 -0.199 -0.026 
Sig. (2-tailed) 0.300 0.217 0.174 0.432 0.822 0.462 0.284 0.891 
N 36 36 36 36 31 31 31 31 
FB+TF Pearson 
Correlation 
-0.141 0.067 -.355* -0.010 -0.185 0.202 0.068 0.224 
Sig. (2-tailed) 0.413 0.699 0.034 0.956 0.328 0.276 0.717 0.225 
N 36 36 36 36 31 31 31 31 
 
Note: FB=Slope of feedback run. TF=Slope of transfer run. FB+TF=Mean slope of FB & TF. **p<.01.*p<.05. °p<.01 
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2.3 Study 3: The role of callous-unemotional traits and aggression subtypes on 
amygdala activity in response to negative faces  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_______________________ 
Submitted as: Aggensteiner, Pascal-M., Holz, NE., Böttinger, B., Baumeister, B. Hohmann, S., Werhahn, J.E., 
Naaijen, J., et al. “The role of callous-unemotional traits and aggression subtypes on amygdala activity in re-
sponse to negative faces“ (Submitted). 
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2.3.1 Abstract 
Background: Brain imaging studies have shown altered amygdala activity during emo-
tion processing in children and adolescents with Oppositional Defiant Disorder (ODD) and 
Conduct Disorder (CD) compared to typically developing children and adolescents (TD). 
Here we aimed to assess whether aggression-related subtypes (reactive and proactive aggres-
sion) and callous-unemotional (CU) traits predicted variation in amygdala activity and skin 
conductance (SC) response during emotion processing. 
Methods: We included 177 participants (n=108 cases with disruptive behavior and/or 
ODD/CD and n= 69 TD), aged 8-18 years, across nine sites in Europe, as part of the EU Ag-
gressotype and MATRICS projects. All participants performed an emotional face-matching 
fMRI task. Differences between cases and TD in affective processing, as well as specificity of 
activation patterns for aggression subtypes and CU traits, were assessed. Simultaneous SC 
recordings were acquired in a subsample (n=63). 
Results:  Cases compared to TDs showed higher amygdala activity in response to neg-
ative faces versus shapes. Subtyping cases according to aggression-related subtypes did not 
significantly influence on amygdala activity; while stratification based on CU traits was more 
sensitive and revealed decreased amygdala activity in the high CU group. SC responses were 
significantly lower in cases and negatively correlated with CU traits and aggression-related 
subtypes. 
Conclusions: Our results showed distinct amygdala activity and SC responses to emo-
tional faces between cases with ODD/CD and TD, while CU traits moderate both central 
(amygdala) and peripheral (SC) responses. Our insights regarding subtypes and trait specific 
aggression could be used for personalized diagnostics and treatment. 
 
 
 
 
 
 
 
Empirical studies 
 
83 
2.3.2 Introduction 
Oppositional defiant disorder (ODD) and conduct disorder (CD) are disruptive behav-
iour disorders which are, with a prevalence rate ranging from 2 to 4% (Polanczyk et al., 
2015), amongst one of the most commonly diagnosed mental health disorders in youth (Loe-
ber, Burke, Lahey, Winters, & Zera, 2000). ODD is characterized by a frequent and persistent 
pattern of irritable and angry mood, vindictiveness, and inappropriate, negativistic, defiant, 
and disobedient behavior toward authorities, while CD is defined as a repetitive and persistent 
pattern of behavior, which violates the rights of others and major age-appropriate societal 
rules (American Psychiatric Association, 2013). The clinical representation of ODD/CD is 
heterogeneous, with distinct subtypes of aggression, and high comorbidity rates with ADHD 
and internalizing symptoms. Moreover, current research suggests that callous-unemotional 
(CU) traits, which include reduced guilt, callousness, uncaring behavior, and reduced empa-
thy, contribute to this heterogeneity (Blair, Leibenluft, & Pine, 2014; Frick & Viding, 2009). 
On this basis, CU traits have been added to the fifth edition of the DSM (DSM-5) as a specifi-
er for the diagnosis of CD called “limited prosocial emotions”. Additionally, two different 
distinctions in reactive (RA) and proactive (PA) aggression is often made to subtype aggres-
sive behavior (Raine et al., 2006). RA is associated with impulsive, high arousal or affective 
aggression whereas PA refers to goal-directed, planned behavior associated with reduced 
arousal and higher levels of CU traits (Blair et al., 2014). 
Recent brain imaging findings have provided insights into the underlying neural 
mechanisms of these aggression-related disorders. Different neural activity patterns of the 
amygdala in children with ODD/CD compared to TD children in response to negative (i.e. 
angry or fearful) face stimuli has been shown (Jones, Laurens, Herba, Barker, & Viding, 
2009; Viding, Sebastian, et al., 2012), suggesting impaired recognition of other’s facial ex-
pressions (Blair, 2013; Veroude et al., 2016). However, previous studies have yielded incon-
sistent findings showing evidence of both hypo-and hyperactivity of the amygdala to affective 
stimuli (Coccaro, McCloskey, Fitzgerald, & Phan, 2007; Herpertz et al., 2005; Passamonti et 
al., 2010). This is consistent with the heterogeneity within aggression-related disorders. Two 
main theories might explain these divergent findings. The threat sensitivity theory which de-
scribes an over-activation of limbic areas (i.e. amygdala) and is presumably associated with 
higher forms of RA, and the deficient empathy theory, which is associated with reduced activ-
ity and more PA and higher CU traits (Blair et al., 2014). Nevertheless, the previously men-
tioned studies did not take subtypes of aggression, and the level of CU traits into account. 
Studies that have considered the influence of CU traits have revealed hypo-activity in youth 
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with high CU traits (CU+) and hyper-activity in the amygdala in children with low CU traits 
(CU-) (Baker, Clanton, Rogers, & Brito, 2015; Blair, Veroude, & Buitelaar, 2016; Viding, 
Fontaine, & McCrory, 2012). Moreover, altered amygdala responses, particularly to fearful 
expressions, showed to be independent of comorbidities, such as ADHD (Hyde et al., 2016; 
Marsh et al., 2008; Posner et al., 2011). Nevertheless, several recent studies did not find any 
significant influence of CU traits on amygdala activity to negative stimuli (Dotterer, Hyde, 
Swartz, Hariri, & Williamson, 2017; Ewbank et al., 2018; Hyde et al., 2016).   
 Heterogeneous findings on the psychophysiological level [i.e. skin conductance re-
sponse (SCR)] might also be explained by aggression-related subtypes. Physiological hypo-
arousal is observed in children with CU+ traits (Fanti, 2016), whereas RA is most commonly 
associated with hyper-arousal, and increased internalizing symptoms (Gao, Tuvblad, Schell, 
Baker, & Raine, 2015; Scarpa, Haden, & Tanaka, 2010). Further, reduced SC (i.e. during rest-
ing state) has been found in ODD/CD (Lorber, 2004; Van Goozen, Matths, Cohen-Kettenis, 
Buitelaar, & Van England, 2000).    
Our study aimed to evaluate if accounting for aggression-related subtypes or CU traits 
in children and adolescents with high aggression, can disentangle the heterogeneity of amyg-
dala responses and SCR to negative face stimuli into more consistent patterns, and to compare 
these responses in participants with ODD/CD to those in a large sample of TD children.  
2.3.3 Materials and Methods 
2.3.3.1 Participants 
Participants in the current study were part of both the EU-Aggressotype and EU-
MATRICS projects. In total 208 participants aged 8-18 years were assessed using a functional 
magnetic resonance imaging (fMRI) across nine sites in Europe. The measures used here were 
part of a larger test battery including questionnaires, neuropsychological testing, MR scanning 
and genotyping. Exclusion criteria for all participants were any contraindications for MRI, an 
IQ<80 measured from four subtests (vocabulary, similarities, block design and picture com-
pletion/matrix reasoning) of the Wechsler Intelligence Scale for Children-IV (Wechsler, D, 
2003) and a primary DSM-5 diagnosis of psychosis, bipolar disorder, major depression and/or 
an anxiety disorder. Participants who were included as “Cases” were diagnosed with ODD 
and/or CD based on the structured diagnostic interviews with child and parents using the Kid-
die Schedule for Affective Disorders and Schizophrenia (K-SADS) (Kaufman et al., 1997) ac-
cording to DSM-5, or scored above the clinical cut-off for aggressive behavior and/or rule-
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breaking behavior as measured with the Child Behavior Checklist completed by parents, 
teachers or youths (CBCL/TRF/YSR; (Achenbach, Howell, Quay, Conners, & Bates, 1991). 
In the typically developing comparison group, no DSM axis I disorder, assessed via the K-
SADS, and no clinical score in the CBCL, TRF or YSR was allowed. For cases, medication 
had to be stable for at least two weeks prior to inclusion The parent-rated Inventory of 
Callous-Unemotional Traits (ICU) (Essau, Sasagawa, & Frick, 2006) and the self-reported 
Reactive-Proactive Aggression Questionnaire (RPQ) (Raine et al., 2006) were used to subtype 
aggressive behavior. ADHD symptoms were measured with the parent-rated SNAP-IV ques-
tionnaire (Bussing et al., 2008).  Ethical approval for the study was obtained for all sites sepa-
rately by local ethics committees. Written informed consent was given by the participants and 
their parents or legal representatives.  
2.3.3.2 fMRI task 
Participants performed a modified version of the emotional face-matching task (Hariri, 
Bookheimer, & Mazziotta, 2000). In this task, participants completed four blocks of a percep-
tual face-matching task in which they had to match the presented emotions. Stimuli comprised 
a trio of faces in which the participants had to select one of two emotions (displayed on the 
bottom) identical to the target stimulus (displayed on the top). Each block consisted of six 
images derived from a standard set of facial affect with either negative (anger and fear) or 
positive faces (happy and neutral). Interleaved between these blocks, participants completed 
two blocks of a sensorimotor control task with geometric shapes (horizontal ellipses or verti-
cal ellipses) (for details see Figure 12).  
 
 
 
 
 
 
 
 
 
 
Figure 12. Modified version of the emotional face-matching task. 
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In this task, participants completed four blocks of a perceptual face-matching task, in which 
they had to match the presented emotion of the upper face to that of the bottom faces (Fear & 
Angry and Happy & Neutral). In addition, participants completed two blocks of a sensorimo-
tor control task, during which a set of geometric shapes was presented. Each of the pictures 
was presented for 4.8s, for a total block length of 28.8s. The total paradigm lasted 231s. 
2.3.3.3 Skin conductance recording and pre-processing 
Skin conductance response (SCR) was recorded simultaneously with fMRI data in 
three sites, using a pair of Ag/AGCI electrodes applying an electrode paste with 0.5% saline 
(TD-246 Skin Resistance–Skin Conductance Electrode Paste, Discount Disposables, Ver-
mont, USA) placed on the distal phalanges of digits I and II on the non-dominant hand. Brain 
products amplifier and MR-capable sensors were used (Brain Products GmbH 
Gilching,Germany). Data were downsampled to 10 Hz and analyzed in Ledalab (Version 
3.4.9; www.ledalab.de) applying the continuous decomposition analysis (CDA) and we ex-
tracted the time integral of the SCR (ISCR) (Benedek & Kaernbach, 2010) for further analy-
sis.  
2.3.3.4 Image acquisition and pre-processing 
MRI scans were performed in nine different sites across Europe (see Supplemental 
Table 23 for site and scanner details). Whole-brain data were acquired with echo-planar T2*-
weighted imaging (EPI), sensitive to the Blood Oxygenation Level Dependent (BOLD) signal 
contrast [36 axial slices (except for one site with 39 slices), 3 mm thickness; repetition time 
2100 ms; echo time 35 ms; voxel size: 3×3×3 mm, Flipangle 74°; FOV=192mm]. Data were 
analyzed using SPM12 (www.fil.ion.ucl.ac.uk/spm/). The first five volumes were discarded to 
allow longitudinal magnetization to reach equilibrium. A high-resolution structural magneti-
zation-prepared rapid gradient echo (MP-RAGE) scan was also acquired at a resolution of 
1×1×1.2 mm. EPIs were interpolated in time to correct for slice time differences and realigned 
to the first scan to correct for head movements. EPIs were co-registered and normalized to the 
T1 standard template in MNI space (Montreal Neurological Institute) using linear and non-
linear transformations, and smoothed with a full-width-half-maximum Gaussian kernel of 8 
mm. Realignment parameters were examined to ensure head movement did not exceed 3 mm.  
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2.3.3.5 Statistical analysis 
2.3.3.5.1 Analysis of demographic and behavioral data 
Group differences in demographic variables were analyzed using analysis of variance 
(ANOVA) or Chi-square tests, when appropriate. Further, behavioral performance data of the 
face-matching task were assessed by repeated measures ANOVA with experimental condition 
(negative faces vs. shapes) as the within-subject factor and a between factor of group. Behav-
ioral data were corrected using age, IQ, medication, sex as covariates of non-interest.  
2.3.3.5.2 fMRI Analysis 
For each participant, a General Linear Model (GLM) assessed regionally specific ef-
fects of task parameters on BOLD indices of activation (Friston et al., 1994). The model in-
cluded experimental conditions (negative and positive faces and shapes), instructions and end, 
plus six realignment parameters as covariates of no interest, to account for residual motion-
related variance. Low-frequency signal drift was removed using a high-pass filter (cut-off 128 
s) and an autoregressive [AR(1)] correction for serial correlations was applied.  
Contrast images for the comparisons of negative faces vs shapes and positive faces vs 
shapes were generated. Since we expected largest effects in the negative faces vs shapes con-
dition, we concentrated on the respective contrast. Exploratory analyses of the positive faces 
vs shapes and negative vs positive faces are reported in the supplementary material. The task 
effect was assessed by means of a one-sample T-test and group differences by a two-sample 
T-test controlling for age, sex, IQ, medication, and site. For group comparisons, several brain 
regions, including amygdala, insula, OFC and ACC were defined as region of interest (ROI) 
thresholded at a corrected FWE <.05 level and corrected for each ROI analysis 
(0.05/4=0.0125). Further, the influence of subtypes of aggression was analyzed applying a 
regression analysis including continuous measurements of RA and PA, separately. Addition-
ally, the influence of the CU traits was analyzed by a regression analysis coding groups as 1 
CU+, 2 TDs, and 3 CU-. Participants for the CU+ group were selected based on the ICU 
means previously published (Lozier, Cardinale, VanMeter, & Marsh, 2014; Sebastian et al., 
2014; Viding, Fontaine, et al., 2012). To obtain a reliable subgroup with CU+ traits in our 
sample, participants had to score ≥38, which represents 27.7% (n=30) of the cases sample.  
Brain regions were defined with the Talairach Daemon atlas implemented in the Wake 
Forest University (WFU) PickAtlas (Lancaster et al., 2000) using the atlas for automated ana-
tomical labeling (Tzourio-Mazoyer et al., 2002). Whole brain analyses are reported at an un-
corrected p<.001 level for clusters including at least 10 voxels.   
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Finally, to account for possible influences of ADHD, we repeated the main analysis 
adding parent-rated ADHD (continuous variable measured with the SNAP-IV questionnaire. 
Sensitivity analyses were performed to rule out more confounding variables, such as site, 
medication, and sex. Additionally, we matched both groups for IQ and age and repeated the 
main analyses. Participants were randomly selected using MedCalc Software 18.9 (MedCalc 
Software, Mariakerke, Belgium) 
2.3.3.5.3 Analysis of skin conductance response (SCR) 
In analogy to the behavioral data, SCR data were analyzed by repeated measures 
ANOVA with within-subject factors experimental condition (negative faces, and shapes), and 
a between-subjects factor of group. Additionally, the relation between SCR, RPQ and ICU 
total score were investigated with Pearson’s correlations. SCRs were defined as responses 
between 0.9 and 4 seconds after stimulus presentation that needed to exceed 0.01µS 
(Boucsein et al., 2012). The SCR amplitude was log-transformed by means of 1+ logSCR to 
obtain normally distributed data.  
2.3.4 Results 
2.3.4.1 Sample characteristics 
Table 21 shows the sample characteristics. From the 208 participants available for 
fMRI analysis; 31 participants were excluded due to excessive motion. Finally, 177 partici-
pants were included for analysis, 69 TDs and 108 cases (43 [39.8%] with ODD, 10 [9.2%] 
with CD alone, 19 [17.6%] with both diagnoses and 36 [33.3%] with a CBCL T-value >70 in 
aggression or rule-breaking behavior. Compared to TDs, the cases group consisted of more 
males (p<.001) lower IQ (p<.001), and did differ marginally with regard to age (p=.078).  
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Table 21. Characteristics of the participants included in the functional magnetic resonance imaging 
analysis 
  
Cases (n=108) 
Control 
(n=69)   ANOVA 
Mean 
Std. Devia-
tion Mean 
Std. Devia-
tion p-values 
Age 13.19 2.69 13.91 2.59 0.078 
Sex(m) 82.4%(m) 
 
58.0%(m) 
 
Chi 
2
<0.001 
IQ 99.28 10.62 107.44 10.69 <0.001 
CBCL T-score Ag-
gression 
74.45 9.99 52.14 3.58 <0.001 
CBCL T-score Rule 
breaking 
67.05 9.05 52.03 3.66 <0.001 
ICU total 32.99 10.02 20.45 7.73 <0.001 
RPQ reactive
b 
  12.40 4.73 5.85 3.54 <0.001 
RPQ proactive
b 
  4.71 4.69 0.88 1.45 <0.001 
RPQ total
b 
  17.11 8.33 6.73 4.42 <0.001 
SNAP IV
c 
  31.14 12.15 5.93 6.62 <0.001 
Medication (%) 60.20% - - - - 
Stimulants 60.00% - - - - 
Antipsychotics 30.76% - - - - 
Antidepressants 4.61% - - - - 
Other 4.61% - - - - 
Note:  CBCL, Child Behavior Checklist; CD, conduct disorder; ICU, Inventory of Callous-
Unemotional Traits; RPQ, Reactive proactive Questionnaire; SANP –IV, ADHD total score; m, male; 
SD, standard deviation; 
a
 IQ estimated from a subset of the Wechsler Intelligence Scale for Children 
III;
 b 
 For cases n= 98; 
c 
For cases n= 81;
 
TD= Typically developing peers. 
 
2.3.4.2 Behavioral data 
Repeated-measures ANOVA for accuracy of correct emotional matching showed only 
a trend for significance between groups [F(1,171)=2.826, p=.095]. Cases showed overall less 
accuracy compared to TDs. As expected, older participants showed a higher accuracy regard-
less of condition (p=.015). All other covariates were not significant. In a further exploratory 
RM-ANOVA with a within condition factor for further separating emotions into angry, fear-
ful, happy, and neutral faces and shapes, the interaction term condition x group was signifi-
cant [F(4,684)=2.805, p=.026]. Post-hoc tests revealed that the cases made more mistakes 
than TD in matching fear (0.018) or neutral faces (<0.001). Regarding reaction times, no sig-
nificant group differences were found [F(1,171)=1.118, p=.292] but a trend for a condition x 
group interaction effect [F(1,171)=2.775, p=.098] was found (for details see Supplemental 
Table 24).  
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2.3.4.3 fMRI task effects 
As reported in prior research using the emotional face-matching task, whole-brain 
analysis of main effects showed robust activation of the amygdala, fusiform area, infe-
rior occipital area, and precuneus, when comparing negative faces with shapes (Figure 
13; for brain activity during the other contrasts see Supplemental Table 25).   
 
Figure 13. Whole brain analysis of main effects showed robust activation of the amygdala, 
fusiform area, inferior occipital area, and precuneus when comparing negative faces vs 
shapes. Whole-brain pfwe-corrected corrected at p<.05. 
 
2.3.4.4 Group comparisons (Cases versus TDs) for negative faces vs shapes 
Figure 14 shows the group comparisons for the amygdala ROI using a t-test, which re-
vealed that cases had higher left amygdala activity compared to TDs [t(165)=3.61, pfwe-
corrected=.008, k=7; x= -27,y= -4, z= -13]. No other effects were found in the ROIs. Group ef-
fects on a whole-brain level are depicted in Supplemental Table 26. For positive faces vs 
shapes see Supplemental Table 27 
 
 
 
 
 
 
t 
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2.3.4.5 Effects of reactive and proactive aggression subtypes  
RPQ measured as a continuous variable did not show any significant association with 
any analyzed ROIs. Only at a trend level a negative relationship with the proactive subscale 
for the left amygdala [t(85)=2.37, pfwe-corrected=.091, K=1, x= -12,y=-1, z=-16] were found in 
cases only. At whole brain level for both groups (at an uncorrected level) a positive relation-
ship with the right fusiform area [t(150)=4.10, puncor<.001, K=15, x= -42,y=-34, z=-16].  
2.3.4.6 Effects of CU traits  
In total, 167 participants were available with complete CU traits data, resulting in 30 
cases CU+ group, 64 TDs, and 73 cases CU- group. Interestingly, CU+ participants were sig-
nificantly older than the CU- subgroup, and showed significantly higher scores for proactive 
aggression (p<.001), but not for reactive aggression. For more details see Table 22.  
 
 
 
 
 
 
Figure 14. Left amygdala activity for ODD/CD vs TD group. ODD/CD group showed higher 
amygdala activity [t(165)=3.61, pfwe-corrected p=.008, k=7; MNI -27;-4;-13].Cases = 
ODD/CD: Oppositional defiant disorder, CD = Conduct disorder, TD= Typically developing 
peers. 
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 Note:  CBCL, Child Behavior Checklist; ICU, Inventory of Callous-Unemotional Traits; RPQ, Reactive proactive Questionnaire; SANP –IV, 
ADHD total score; SD, standard deviation; 
a
 IQ estimated from a subset of the Wechsler Intelligence Scale for Children III;, CU -  = Low 
ICU, CU += High ICU, TD= Typically developing peers.
Table 22. Characteristics of the participants included in the regression analysis 
   
  
CU - TD  CU +  ANOVA Post-hoc 
n Mean SD n Mean SD n Mean SD p-values   
Age 72 12.75 2.64 64 13.93 2.54 30 13.91 2.77 0.019 CU - < TD = CU +  
Sex(m) 72 84.9%  64 56.30%  30 83.30%  Chi 
2
<0.001 TD < CU - = CU + 
Medication (%) 72 
53.4% 
 
64 0.00% 
 
30 63.30% 
 
Chi 
2
<0.001 TD < CU - = CU + 
IQ 72 99.71 9.99 64 107.81 10.87 30 99.61 12.10 <0.001 CU - = CU + < TD 
CBCL T-score Rule breaking 72 64.92 8.79 64 52.09 3.74 30 72.84 7.52 <0.001 TD < CU - <CU + 
CBCL T-score Aggression 72 73.72 10.65 64 52.22 3.65 30 76.83 7.97 <0.001 TD < CU - = CU + 
ICU total 72 27.89 5.96 64 20.45 7.73 30 45.23 6.55 <0.001 TD < CU - < CU + 
RPQ reactive 69 12.24 4.50 63 5.83 3.55 29 13.10 5.05 <0.001 TD < CU - = CU + 
RPQ proactive 69 3.59 3.90 63 0.90 1.48 29 7.45 5.56 <0.001 TD < CU - < CU + 
RPQ total 69 15.82 7.24 63 6.73 4.47 29 20.55 9.68 <0.001 TD < CU - < CU + 
SNAP -IV 58 28.80 10.87 61 5.92 6.75 23 38.74 12.41 <0.001 TD < CU - < CU + 
Medication (%) 
 
52.0% 
     
63.3% 
 
ns CU - = CU + 
Stimulants  73.6% 
    
 47.3% 
 
Chi 
2  
= 0.040 CU - > CU + 
Antipsychotics  31.5% 
    
 36.8% 
 
ns CU - = CU + 
Antidepressants  5.2% 
    
 5.2% 
 
ns CU - = CU + 
Other   2.6%       10.5%  ns CU - = CU + 
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Regression analysis showed a significant association with left amygdala activity 
[t(153)=3.27, pfwe-corrected=.012, K=3,x=-12,y=-1, z=-16]. The CU+ group showed lower 
amygdala activity for negative faces versus shapes, whereas the CU- group showed higher 
activity compared to the CU+ and TD (Figure 15). The whole-brain analysis is depicted in 
Supplemental Table 28. For the positive faces versus shapes contrast, no significant group 
difference or an association with CU traits was found. 
 
 
 
 
 
2.3.4.7 Sensitivity analyses 
2.3.4.7.1 ADHD as a covariate 
To control for potential influences of ADHD symptoms, we added the SNAP IV as a 
covariate. In total, 158 participants were available with complete ADHD symptom data. The 
inclusion of this covariate further strengthened the results with higher amygdala activation in 
cases [left amygdala t(143)=3.63, pfwe-corrected=.008, k=16; x= -24, y= -4, z= -13; right amyg-
dala t(143)=3.35, pfwe-corrected=.018, k=16;x= 27,y= -4, z= -13]. The whole-brain analysis is 
shown in Supplemental Table 29.  
Figure 15. Group-specific amygdala activity for negative vs shapes contrast depending on the 
CU subtypes  [t(153)=3.27, pfwe-corrected =.012, K=3,x=-12,y=-1, z=-16]. CU + = High callous-
unemotional traits, TD= Typically developing peers, CU - = Low callous-unemotional traits. 
Empirical studies 
 
94 
2.3.4.7.2 Analysis in non-medicated participants  
Use of medication was related to amygdala activity [F(1,164)=7.814, p=.006], with 
higher amygdala activity during the negative versus shapes contrast in non-medicated partici-
pants  [t(164)=3.32, pfwe-corrected p=.010, k=8, x=-15, y=2, z=-16]. Likewise, the main result of 
higher amygdala activity in patients remained unchanged, when only non-medicated partici-
pants were included in the analysis [t(100)=3.40, pfwe-corrected=.008, k=16, x= -24,y=-4, z=-13; 
for whole-brain analyses see Supplemental Table 30]. 
2.3.4.7.3 Site, age, and sex effects 
There was a significant effect of site on amygdala activity [F(8,164)=2.259, p=.026]. 
Nevertheless, when excluding four sites with fewer than 5 participants per group, and no ef-
fect of site remained [F(8,131)=1.159, p=.181], the results did not change [t(131)=3.53, pfwe-
corrected=.011, k=19, x=-24, y=-4, z=-13]. In addition, there was no significant effect of age and 
sex. For details, see Supplemental Table 31 and Table 32.  
2.3.4.8 Skin conductance  
Simultaneous fMRI and skin conductance data were available for 38 cases and 26 
TDs. A significant interaction between experimental condition and group was found 
[F(1,62)=5.352, p=.024]. In the cases group, a lower skin conductance response to negative 
facial stimuli (p=.002), but not to shapes (p=.252) was seen compared to TDs. The total score 
on the ICU scale was negatively associated with SCR for negative faces (r=-.393, p=.001) and 
shapes (r=-.295, p=.019) (Figure 16). Additionally, significant correlations between RA (r=-
.293, p=.020), PA aggression (r=-.277, p=.028) and RPQ total scale (r=-.320, p=.010) were 
found for SCR of negative faces only.  
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2.3.5 Discussion 
Our study addressed the neural characterization of aggression-related subtypes and CU 
traits in children and adolescents with ODD/CD from a large multicenter cohort during a 
well-established and robust fMRI task. Cases showed higher amygdala activity during the 
presentation of negative faces versus shapes than TDs. This finding is in line with literature 
suggesting that individuals with ODD/CD show divergent neural activity and deficient face 
and emotion processing (Blair et al., 2014). Regarding subtypes of aggression, we did not find 
any significant association that survived family-wise correction, but there was a trend for a 
negative relationship between PA and amygdala activity to negative faces. With regard to CU 
traits, we demonstrated trait-specific alterations in the amygdala for negative faces. This find-
ing is in line with previous studies showing higher amygdala activity in youth with low CU 
traits, but lower activity in those with high CU traits (Viding et al., 2014).  
The general higher activity in the amygdala adds evidence to the heightened threat 
sensitivity theory in aggression-related disorders (Blair et al., 2014; Dotterer et al., 2017; Vid-
ing, Fontaine, et al., 2012). Importantly, this effect remained stable after controlling for age, 
sex, medication, site, IQ, ADHD, and internalizing symptoms. Additionally, this higher 
Figure 16. Skin conductance response activity to negative faces. ICU was nega-
tively associated with SCR and the CU – subgroup showed less SCR response 
ODD/CD: Oppositional defiant disorder, CD = Conduct disorder, TD= Typically devel-
oping peers, CU + = High callous-unemotional traits,  CU - = Low callous-unemotional 
traits. ICU=Inventory of callous-unemotional traits. *p<.05. 
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amygdala activity showed a phenotype-specific pattern for participants with significantly 
lower PA.    
Concerning the differential effect of CU traits, our results showed that these traits are 
able to disentangle specific neural alterations, which is in line with previous findings (Jones et 
al., 2009; Lozier et al., 2014; Marsh et al., 2008; Viding et al., 2014; White et al., 2012).  It is 
worth noting, that in our study, only the most severe callous-unemotional patients (ICU>38) 
showed specific amygdala under-activation. Earlier studies using the same instrument, found 
CU-specific amygdala activity, in an even higher CU traits population (ICU mean 52) (Lozier 
et al., 2014; Sebastian et al., 2014; Viding, Fontaine, et al., 2012). In our opinion, this finding 
might be an important additional result that provides a cut-off (ICU ≥ 38) which could be 
used in the classification of aggression-related disorders (specifier) and probably subtypes. 
Interestingly, the phenotype of the CU+ subgroup showed higher scores for PA compared to 
the CU- subgroup. However, no differences between high and low CU subgroups were found 
for RA. Some studies showed that both aggression-related subtypes are associated with high 
CU traits (Kimonis et al., 2008; Pechorro, Ray, Gonçalves, & Jesus, 2017; Waller et al., 
2015), while one study reported that only PA is correlated with CU traits (Urben et al., 2018). 
These mixed findings might suggest that CU traits measured via the parent reported ICU 
questionnaire is more sensitive than the self-reported RPQ questionnaire. 
Finally, the skin conductance data showed general physiological hypo-activation in re-
sponse to negative in cases compared to TDs. This finding is in line with numerous studies ( 
Blair, 1999; Fanti, 2016; Herpertz et al., 2005, 2008) showing reduced skin conductance in 
aggression-related disorders. However, the SCR and fMRI data showed divergent patterns 
with higher amygdala activity in the CU- subgroup when compared with TDs, and a negative 
association between SCR, CU traits, PA and RA. This, together with the overall reduced SCR 
might suggest an interrupted physiological circuit with neural processes involved in response 
to affective stimuli in cases within the CU- subgroup. However, this should be interpreted 
with caution, since our fMRI-SCR data was only based on a small number of cases. 
2.3.5.1 Strengths and Limitations 
The strengths of this study include a large sample of cases with ODD/CD and TD 
children and adolescents, the assessments of reactive and proactive aggression and CU traits, 
enabling to disentangle subtype and trait-specific differences, and a well-established fMRI 
task to elicit amygdala activity. There are also limitations worth noting. First, the multicenter 
nature of this study, in which nine different institutes participated and contributed to a sample 
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size which would have been difficult to reach at an individual site, might have also introduced 
heterogeneity. However, sensitivity analysis with fewer sites did not change the main results, 
indicating that this did not negatively influence the results. Second, our relatively small pro-
portion of subjects high in CU traits (29.1%) suggests that our cases sample is predominantly 
reactively aggressive, since there were no significant differences between low and high CU 
subgroup. Moreover, within this emotional face-matching task, the negative faces comprised 
two emotions (fear and angry) which could have diluted our effects as studies which showed 
CU effects on amygdala activity found mainly effects for fearful faces (Jones et al., 2009; 
Lozier et al., 2014; Marsh et al., 2008; Viding, Fontaine, et al., 2012). Interestingly, this is 
confirmed by our performance data with fewer correct responses specifically during the 
matching of fearful faces.  
2.3.5.2 Conclusion 
In summary, this large study compared children and adolescents with aggression-
related problems to TD peers during an fMRI emotional face-matching task, taking subtypes 
of aggression and CU traits into account. Overall, children and adolescents with high aggres-
sion showed amygdala hyper-activity in emotion and face processing areas, particularly in the 
subgroup with low CU traits. In contrast, in those with high CU traits, amygdala hypo-activity 
was observed. Our findings underline the importance to specify subtypes and CU traits in ag-
gression-related disorders, based on top-down evidence and therefore providing a possible 
biomarker, which could be used for personalized diagnostics and treatments. 
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2.3.6 Supplementary material 
Table 23. Site and scanner details 
 
Functional magnetic resonance imaging (fMRI) across nine sites in Europe (Radboud 
University Medical Center and the Donders Institute for Brain, Cognition and Behavior, Nij-
megen, The Netherlands; Department of Neuroscience, University Medical Center Groningen, 
The Netherlands; Central Institute of Mental Health (CIMH), Mannheim, Germany; Depart-
ment of Psychiatry III and Child and Adolescent Psychiatry/Psychotherapy, University of 
Ulm, Ulm, Germany; Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology 
and Neuroscience, King’s College London, London, United Kingdom; Department of Child 
Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, 
London, United Kingdom; Department of Child and Adolescent Psychiatry and Psychology, 
Neurosciences Institute, Hospital Clinic de Barcelona, Barcelona, Spain; Hospital Gregorio 
Marañón, Madrid, Spain; MR Center, Psychiatric University Hospital, Zurich, Switzerland; 
IRCCS Santa Lucia Foundation, Rome, Italy. 
 
 
Scanner Site TR/TE (ms) 
Number of 
slices 
Slice scan order 
Voxel 
size 
(mm) 
Siemens  Nijmegen 2100/35 36 descending 3x3x3 
 
Mannheim 2100/35 36 descending 3x3x3 
Ulm 2100/35 36 descending 3x3x3 
 Barcelona 2100/35 36 descending 3x3x3 
 Madrid 2100/35 36 descending 3x3x3 
 Rome 2100/35 36 descending 3x3x3 
Philips Groningen 2100/35 39 descending 3x3x3 
 Zurich 2100/35 36 descending 3x3x3 
GE* London 2100/35 
 
36 
descending, inter-
leaved 
3x3x3 
*All sites used a 32-channel head coil except for the General Electric 3-Tesla scanner (8-channel head coil).    
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Table 24. Behavioral data – Accuracy and Reaction times 
  
Accuracy 
 
Reaction time 
 
Emotion Group 
Mean 
(%) SD p-value Mean (s) SD p-value 
Anger TD 83.82 17.61 
.147 
2.22 0.49 
.173 
 
Cases 76.25 24.10 2.38 0.58 
Fear TD 93.72 11.47 
.018 
1.94 0.45 
.030 
 
Cases 87.41 18.68 2.16 0.48 
Happy TD 86.72 17.29 
.228 
1.97 0.48 
.314 
 
Cases 80.52 21.09 2.09 0.50 
Neutral TD 94.93 11.89 
<.001 
1.95 0.44 
.582 
 
Cases 83.32 23.13 2.01 0.50 
Shapes TD 90.94 13.39 
.404 
1.43 0.49 
.975 
  Cases 84.13 20.37 1.50 0.53 
Note: TD: Typically developing peers, Cases = ODD/CD: Oppositional deviant disor-
der/Conduct disorder.  Bonferroni corrected. 
 
 
Table 25. Whole brain analysis for task effect (Negative vs Positive contrast) 
Region Voxel size Peak level MNI coordinates (mm) 
  T Z-score p-FWE x y z 
Temporal_Mid_R 61 6.00 5.59 0.000 57 -61 2 
16 5.13 4.93 0.007 54 -43 8 
Temporall_Sup_R 5 5.04 4.85 0.010 48 -31 -1 
Temporal_Mid_L 4 4.86 4.69 0.019 -48 -52 8 
        
Brain regions were defined using the Automated anatomical labeling (AAL).   
Table 26. Whole brain analysis for negative vs shapes between Cases and TDs 
Region Voxel size Peak level MNI coordinates (mm) 
  T Z-score p(unc) x y z 
Left superior occipital area 31 3.73 3.65 0.000 -24 -91 23 
Frontal_Inf_Oper_L 59 3.69 3.61 0.000 -51 11 23 
 3.67 3.59 0.000 -45 20 32 
Left amygdala 10 3.61 3.54 0.000 -27 -4 -13 
Left inferior parietal gyrus 13 3.48 3.41 0.000 -36 -61 53 
Brain regions were defined using the Automated anatomical labeling (AAL).   
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Table 27. Whole brain analysis for positive vs shapes between Cases and TD 
Region Voxel size Peak level MNI coordinates(mm) 
  
T Z-score p(unc) x y z 
Not labeled 20 4.11 4.00 0.000 9 2 -10 
Occipital_Sup_L 28 4.09 3.98 0.000 -18 -94 29 
Olfactory_L 
22 3.97 3.88 0.000 -3 11 -10 
 
3.63 3.55 0.000 -6 -1 -13 
Frontal_Mid_R 45 3.87 3.78 0.000 33 26 50 
Frontal_Sup_R 
 
3.45 3.39 0.000 24 38 44 
 
3.29 3.23 0.001 24 23 62 
Frontal_Inf_Orb_R 
21 3.74 3.66 0.000 24 14 -25 
 
3.69 3.62 0.000 18 17 -19 
Frontal_Med_Orb_L 12 3.62 3.54 0.000 -9 44 -13 
Frontal_Med_Orb_R 
26 3.62 3.54 0.000 6 50 -7 
 
3.34 3.28 0.001 15 41 -10 
 
3.23 3.17 0.001 6 38 -13 
Postcentral_R 
32 3.60 3.52 0.000 51 -13 -25 
 
3.59 3.52 0.000 54 2 -28 
Brain regions were defined using the Automated anatomical labeling (AAL).   
 
Table 28. Regression analysis parent ICU total scale. Whole brain analysis 
Region Voxel size Peak level MNI coordinates (mm) 
  
T Z-score p(unc) x y z 
Cingulum_Post_L 81 4.44 4.30 0.000 -6 -43 11 
Temporal_Sup_R 14 4.15 4.03 0.000 45 -7 -13 
Not labeled 
70 4.06 3.95 0.000 -18 47 -1 
 
3.66 3.58 0.000 -15 35 -1 
 
3.58 3.50 0.000 -27 47 -4 
Precuneus_L 47 3.80 3.70 0.000 0 -73 47 
Cuneus_R 
 
3.43 3.37 0.000 3 -79 38 
Parietal_Inf_L 13 3.65 3.57 0.000 -36 -73 47 
Cingulum_Mid_L 17 3.61 3.53 0.000 -9 -43 38 
Insula_L 13 3.50 3.43 0.000 -36 -1 -1 
Brain regions were defined using the Automated anatomical labeling (AAL).   
Note: The influence of the CU traits were analyzed coding group as 1 ODD/CD CU+, 2 Typically 
developing children and 3 ODD/CD CU-.  
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Table 29. Correcting for ADHD 
Region Voxel size Peak level MNI coordinates (mm) 
  
T Z-score p(unc) x y z 
Frontal_Mid_L 157 4.47 4.32 0.000 -36 -52 23 
Occipital_Mid_L 
 
4.00 3.89 0.000 -33 -70 32 
  
3.31 3.25 0.001 -45 -43 29 
Frontal_Inf_Tri_L 35 4.18 4.05 0.000 -51 14 23 
Frontal_Inf_Tri_R 42 3.98 3.87 0.000 51 41 5 
Precuneus_R 
49 3.81 3.71 0.000 6 -76 35 
 
3.45 3.37 0.000 9 -58 26 
Occipital_Sup_L 35 3.81 3.71 0.000 -21 -91 20 
Rectus_L 
15 3.68 3.59 0.000 0 41 -16 
 
3.55 3.47 0.000 -6 50 -16 
 
3.19 3.13 0.001 3 53 -16 
Frontal_Mid_Orb_R 14 3.66 3.57 0.000 27 35 -13 
Amygdala_L 28 3.63 3.54 0.000 -24 -4 -13 
Hippocampus_L 
 
3.41 3.34 0.000 -15 -7 -16 
Occipital_Mid_R 31 3.62 3.53 0.000 33 -79 23 
Putamen_R 17 3.50 3.42 0.000 33 2 -4 
Amygdala_R 
 
3.35 3.28 0.001 27 -4 -13 
Brain regions were defined using the Automated anatomical labeling (AAL).  ADHD = Attention defi-
cit and hyperactivity disorder. ADHD was measured with the SNAP IV questionnaire.  
 
Table 30. Non-medicated participants only. Negative vs Shapes 
Region Voxel size Peak level MNI coordinates (mm) 
  
T Z-score p(unc) x y z 
Frontal_Mid_L 136 4.26 4.07 0.000 -48 23 32 
Frontal_Inf_Oper_L 
 
3.95 3.80 0.000 -51 11 23 
Precentral_L 
 
3.56 3.45 0.000 -51 11 35 
Parietal_Inf_L 38 3.80 3.66 0.000 -36 -67 47 
Not labeled 10 3.66 3.53 0.000 -36 -49 35 
Frontal_Mid_L 15 3.60 3.48 0.000 -27 5 53 
Not labeled 22 3.58 3.47 0.000 -21 -43 47 
Brain regions were defined using the Automated anatomical labeling (AAL).     
Note: This analysis was based on 44 ODD/CD children and 69 typically developing peers.  
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Table 31 ANCOVA with ROI left Amygdala activity 
Tests of Between-Subjects Effects 
Dependent Variable:  Left Amygdala_ROI  [Negative faces vs Shapes] 
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 9.918
a
 13 .753 2.614 .002 
Intercept .000 1 .000 .000 .989 
Group 3.471 1 3.471 11,89 .001 
Sites 5.274 8 .659 2.259 .026 
Age 0.006 1 .006 0.19 .890 
Medication 2.280 1 2.280 7.814 .006 
Gender .057 1 .057 .196 .658 
IQ .133 1 .133 .455 .501 
Error 47.860 164 .292   
Total 63.166 178    
Corrected Total 57.778 177    
a. R Squared = .172 (Adjusted R Squared = .106) 
ROI = Region of interest.  ANCOVA= Analysis of covariance. Fixed factors:  Sites and Group. Co-
variates: Age, Sex, IQ and Medication.  Significant impact of group and medication for the left amyg-
dala activity was found. Amygdala activity showed to differ between Sites, sex and age.  
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Table 32. ANCOVA with ROI left Amygdala activity excluding sites with less than 5 partici-
pants for each group 
Tests of Between-Subjects Effects 
Dependent Variable:   Left Amygdala_ROI  [Negative faces vs Shapes] 
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 6.993
a
 9 .777 2.569 .009 
Intercept .015 1 .015 .049 .824 
Group 3.559 1 3.559 11.770 .001 
Sites 1.924 4 .481 1.591 .181 
Age .024 1 .024 .078 .780 
Medication 2.227 1 2.227 7.366 .008 
Gender .325 1 .325 1.074 .302 
IQ .212 1 .212 .701 .404 
Error 39.613 131 .302   
Total 50.373 141    
Corrected Total 46.606 140    
a. R Squared = .150 (Adjusted R Squared = .092) 
ROI = Region of interest.  ANCOVA= Analysis of covariance. Fixed factors:  Sites and Group. Co-
variates: Age, Sex, IQ and Medication.  Significant impact of group and medication for the left amyg-
dala activity was found. Amygdala activity showed not to differ between Sites, sex and age 
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2.4 General Discussion 
In this thesis, three main hypotheses were evaluated in a large multicenter randomized 
controlled trial comparing NF for children with ADHD to a semi-active control condition. 
First, we assessed the specificity of SCP-NF in children with ADHD by controlling for un-
specific effects, and assessing self-regulation of slow-cortical potentials. Second, we looked at 
sustained and long-term effects six-month after treatment, and third, we assessed the modula-
tion by and the effects on comorbid aggression. Importantly, this is the largest RCT assessing 
NF treatments in an ADHD outpatient sample to date (at least to the best of our knowledge). 
Additionally, we evaluated aggression-relevant subtypes in a large multicenter cohort of chil-
dren and adolescents with disruptive behaviors and high comorbidity with ADHD, during a 
well-established and robust fMRI task, which might be useful for identifying new NF targets, 
and therefore for personalized treatment options.  
The main findings of the studies reported here can be summarized as follows: (1) The 
SCP-NF group showed significantly greater symptom reduction than the comparison group on 
the primary parent-rated outcome, which in turn, might be interpreted as a confirmation of 
specific effects, given the strong control for unspecific effects by the semi-active EMG-BF 
control group. (2) An additional important hint for specificity is that we could demonstrate 
successful self-regulation of SCP, although the lack of prominent self-regulation learning and 
correlations with clinical outcomes limit these conclusions. (3) SCP-NF showed stable and 
large effects six-month after treatment end, suggesting long-lasting effects. (4) After SCP-NF, 
comorbid aggression symptoms were reduced, but mostly independent of group allocation; 
nevertheless, reduction of comorbid aggression correlated with SCP-NF self-regulation only, 
and (5) we provide a possible biomarker for subtype-specific aggression, which could be used 
for personalized NF treatments.  
These main findings are highly relevant and provide additional important evidence 
that specific NF protocols, such as SCP-NF can be useful in treating ADHD. However, there 
are still important aspects which should be taken into account. In our first study, we showed 
that SCP-NF was significantly superior to the semi-active control group, with a medium to 
large effect size on the primary outcome. This effect was only seen for the more proximal 
parent ratings and not for the probably blinded teacher ratings. A comparable pattern of re-
sults was obtained in the meta-analysis of the European ADHD Guidelines Group, leading 
them to conclude that the current evidence failed to support NF as an effective treatment for 
ADHD, since no significant effect were found for probably blind teacher ratings (Cortese et 
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al., 2016). A significant advantage for standard protocols such as SCP-NF in probably blinded 
ratings in an exploratory analysis (Cortese et al 2016) could not be replicated here, except for 
the significant but uncontrolled within-group comparison. Conversely, to date, there is also an 
important recent debate about how the source of evaluation (i.e. parent, teacher ratings, or 
observers) also affects the sensitivity to assess ADHD symptom improvement. So far, current 
meta-analyses are considering teacher ratings or classroom observers mainly as probably 
blinded and therefore unbiased. This is because teacher ratings arise from a different context 
than the one where the training takes place (Sonuga-Barke et al., 2013). Strikingly, a recent 
study from Minder et al (2018), assessed the source of evaluation controlling for the context 
where these trainings were applied. Overall, the results of this RCT showed that teachers are 
at least as sensitive to waiting time effects as parents, but less sensitive than parents to behav-
ioral change during the actual treatment phase, and thus did not support the assumption that 
teachers were more objective. Therefore they challenged the conclusion of the current meta-
analyses. Besides this, one recent review of previous meta-analyses including the most recent 
RCTs showed that NF significantly improves inattention symptoms also for probably blinded 
raters with small effect sizes (Riesco-Matías et al., 2019). Additionally, in our RCT (study 1 
and 2), the teacher ratings were not different between groups, but within-group analysis 
showed that symptom improvement was higher for the SCP-NF group with small to medium 
effect sizes. Interestingly, an additional new meta-analysis from Bussalb et al. (2019) which 
looked explicitly at the effects for probably blinded rates for standard NF protocols (in line 
with Cortese et al., 2016) found significant teacher ratings including the most recent two RCT 
(Streh & Aggensteiner, et al., 2017) and Baumeister et al., 2018), except for hyperactivity 
subscale.  
With regard to the specificity of SCP-NF, our studies addressed two major aspects: 
First, the semi-active control group, as discussed in Strehl & Aggensteiner et al (2017), con-
trols for unspecific effects, such as training setting, interaction, learning, time, motivation, 
trained parameters, and effort. Controlling for these factors is highly important since the clini-
cal effects of this kind of time-consuming training might otherwise be attributed to psychoso-
cial effects (Wood & Kober, 2018) which are not related to the self-regulation of neurophysi-
ological states targeted by the NF training itself. A recent review highlighted that NF effects 
might be dominated by placebo effects (Thibault & Raz, 2017). Furthermore, NF training 
might be highly influenced by the participant’s motivation, beliefs, and high-tech settings. To 
control for these aspects, a sham-feedback condition is often proposed and considered as a 
gold standard in intervention research (Schönenberg et al., 2017). However, sham-control has 
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also received some criticism. For instance, these kinds of sham-protocols use automatic 
thresholding which might prevent learning. Additionally, the use of sham conditions for NF 
treatments might be critically affecting motivation, since the lack of success in the first active 
NF session may lead to the impression of being allocated to an ineffective control condition 
(Strehl & Aggensteiner et al., 2017). Further, patients and trainer might detect the sham con-
dition and may refuse further participation (Birbaumer, 1991). Therefore, it is an important 
aspect to select an adequate control group or condition. Other active control conditions, as for 
instance, pharmacotherapy do not control for unspecific effects as the variables of interest, 
motivation, time, effort cannot be controlled for. Considering all these points, there is proba-
bly not a single perfect control group or condition which is able to resolve all the above-
mentioned complex questions.  
 In addition to the selection of the comparison group (EMG-BF) which controlled for 
most unspecific effects, we addressed the key question regarding evidence to the specificity of 
NF approaches, by examining the self-regulation of the trained parameters and its correlates. 
These are of paramount importance since the assumption that NF allows subjects with ADHD 
regulate deviant cortical excitation, which reflects cognitive and motor preparation, are only 
less systematically tested and reported. In study 1, we demonstrated successful self-regulation 
of the SCP-NF participants. First, we showed that participants were able to modulate cortical 
excitation, which means that they performed according to their task (to produce negative or 
positive cortical shifts). However, we could only show significant self-regulation through re-
al-time feedback condition. During the transfer condition, we could not find any significant 
difference. The transfer condition is considered as the most important one since it should help 
to transfer the learned skills into daily life (i.e. school settings) (Strehl et al., 2006). This rais-
es the possibility that more transfer and training session might be necessary to acquire trans-
ferred self-regulation skills. Additionally, it has been discussed that self-regulation, particular-
ly for the transfer condition might show delayed learning. It has been shown that the perfor-
mance in transfer trials improved substantially 6-month after training (Kotchoubey et al., 
1999; Strehl et al., 2006). Interestingly, in our study 2, we could also demonstrate significant 
enhancement of self-regulation in the transfer skills six-month after training.  
With regard to the association between clinical outcome and regulation of the trained 
parameters, our study 2 could only add limited evidence for such an association. As discussed 
in Aggensteiner et al., (2019), we obtained unexpected and mixed outcomes. Nevertheless, 
only very few studies reported so far this kind of associations (Drechsler et al., 2007; Gevens-
leben et al., 2009; Janssen et al., 2016; Strehl et al., 2006). Our studies, therefore, provide 
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important insights and matches the new consensus on reporting RCT regarding NF (Ros et al., 
2019). Concerning the associations between self-regulation and clinical outcomes, we could 
show significant correlation for secondary outcomes only. Significant correlation with impul-
sivity and a trend for hyperactivity rated by parents and teachers one month after treatment 
end, nevertheless, the semi-active control group showed as well significant associations at 
follow-up. It is therefore complicated to disentangle specific from unspecific effects looking 
only at correlational data. Since both groups showed clinical improvement, and both groups 
had some enhancement of self-regulation skills, the correlations might be more spurious and 
unspecific than specific. Besides self-regulation, electrophysiological pre-post changes should 
be also taken into account (Doehnert et al 2008; Zuberer, Brandeis, & Drechsler, 2015) to be 
able to disentangle specific from unspecific effects.  
Concerning sustained and long-term clinical effects, our study 2 provided clinical out-
come six-month after treatment. The SCP-NF showed stable clinical improvement directly 
after treatment end. However, there were no significant differences in improvement between 
the two groups, which in turn might suggest strong unspecific effects common to both NF and 
EMG-BF training. Nevertheless, as discussed above, the selection of a good control group is 
crucial. In our study 1 and 2, we decided to use a different biofeedback modality which was 
electromyographic biofeedback, which is considered as a semi-active control condition (Arns 
et al. 2013). An alternative semi-active condition could be cognitive training.  It should be 
noted that this kind of trainings (i.e. EMG-BF and Cognitive training) already showed some 
clinical improvements in ADHD population with small to medium effect sizes for unblinded 
raters ( EMG-BF: Aggensteiner et al., 2019; Barth, Mayer, Strehl, Fallgatter, & Ehlis, 2017; 
Maurizio et al., 2013; Cognitive training: Minder et al., 2018; Cortese et al., 2015). Therefore, 
the comparison with control conditions which already showed specific clinical improvement 
themselves might dilute clinical and specific effects. This might resemble the findings of a 
recent meta-analysis that analyzed sustained and long-term effects after NF in comparison 
with active and non-active control groups.  This meta-analysis showed that at follow-up, NF 
was clinically superior to the non-active groups, and that the effects were similar to the active 
groups (van Doren et al., 2018).  
With regard to comorbid aggression and the effects of NF, we showed significant 
symptom reduction irrespective of group. Since only a few studies reported significant impact 
on comorbid aggression after NF, our findings, with no group-specific effects, highlights that 
there is a gap of knowledge for which NF training modality could be used to target aggres-
sion-related symptoms. Furthermore, since aggression-related problems show two distinct 
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phenotypes (reactive and proactive aggression) our study 3 might provide more insights with 
regards to this.  
As already mentioned, study 3 aimed to disentangle the heterogeneity of aggression-
related problems at a neural and peripheral level which reflects the activity of the autonomous 
nervous system. We showed that children and adolescents high on aggression showed amyg-
dala hyper-activity during an emotion and face processing task, particularly in the subgroup 
with low CU traits. In contrast, in those with high CU traits and scoring high on proactive 
aggression, amygdala hypo-activity was observed. This finding is in line with previous studies 
(Jones et al., 2009; Lozier et al., 2014; Marsh et al., 2008; Sebastian et al., 2014; White et al., 
2012). Additionally, we showed that this subtype-specific pattern could be demonstrated also 
at a peripheral level, with lower SC response for those children and adolescents with high 
proactive aggression and CU traits, which is also in line with previous findings (Fanti, 2016; 
Herpertz et al., 2008). Although, we found a general under-activity in children and adoles-
cents with aggression-related problems compared to TDs. Which indicates a divergent pattern 
between central and peripheral indices of arousal for children and adolescents with aggres-
sion-related problems. This novel insight might suggest an interrupted physiological circuit 
with neural processes involved in response to affective stimuli. Putting together these find-
ings, we might provide two distinct targets for new NF treatment modalities. Children and 
adolescents with higher proactive aggression and high on CU traits might potentially benefit 
from up-regulation of the amygdala activity and more reactive and impulsive aggression 
might benefit form down-regulation of the amygdala activity. Additionally, the findings of 
SCR might potentially suggest, that this peripheral measurement, might act as a proxy for 
both aggression-related subtypes, since a general under-activity was found for SCR, thus, NF 
training aiming to up-regulate SCR might be beneficial for both subtypes.  
2.5 Limitations 
In this section, the major shortcomings of the three studies forming this thesis are 
listed. First, with regards to the SCP-NF RCT (Study 1 and 2), a main limitation is the overall 
low self-regulation performance. As already discussed in Aggensteiner et al., 2019, the mean 
performance or reinforcement rate was 44% for SCP-NF. In contrast, the EMG-BF rein-
forcement rate was 82%. These SCP-NF reinforcement rates still are in line with the few stud-
ies that reported these outcomes (Baumeister et al., 2016; T. Takahashi, 2013). This might 
suggest that self-regulation of brain-related activity is far more difficult than body-related 
self-regulation, and therefore future studies should ensure sufficient learning after SCP-NF. A 
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second main limitation of the SCP-NF RCT might be that in both treatments pharmacotherapy 
was allowed. Despite that in study 1, a two to four weeks washout was implemented, at 
follow-up, this was not the case and probably added a confounding factor, although sensitivity 
analysis with non-medicated participants was performed and no changes of the main results 
were obtained. A third shortcoming, regarding aggression-related comorbidities, was that we 
only assessed these symptoms via the SDQ, which might limit our generalizability for these 
comorbidities. A fourth constraint might be the kind of feedback modality which was provid-
ed by the neurofeedback software. This old-fashioned (2-D images) method (see Figure 3) 
might not be appropriate for children and adolescents born in a more “digital world”, and 
therefore newer methods that use 3D rendered images (Alegria et al.,2018) or virtual reality 
settings might lead to higher self-regulation and motivation. Finally, with regards to the study 
3, the main limitation was the relatively small proportion of subjects high on CU traits and the 
chosen emotional face-matching task. These two points could have diluted the shown effect of 
CU traits on amygdala activity.  
2.6 Outlook 
Although the presented RCT showed long-lasting clinical impact on ADHD core 
symptoms and comorbid conduct problems, further well-controlled RCT are warranted to 
disentangle specific form unspecific effects of NF treatment. New studies, as already dis-
cussed above, should ensure enough self-regulation and learning, in particular in the transfer 
trials (i.e. providing more training sessions and giving some instructions/feedback after an 
intermediate evaluation of the learning/performance). Additionally, extending the follow-up 
assessment period (i.e. two years) might be of particular interest, since long-lasting effects 
(beyond six months) are less systematically studied. Moreover, different semi-active control 
groups (fNIRS, MEG or real-time fMRI feedback) might provide additional insights which 
probably could fully disentangle specific form unspecific effects.  
With regard to NF targets for aggression-related problems, specific RCT such as those 
investigated in the EU-projects Aggressotype (skin conductance biofeedback) and MATRICS 
(amygdala/insula real-time fMRI) are needed to assess the effects of arousal-related parame-
ters on aggressive behavior.  
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3. SUMMARY 
The present thesis focused on specificity and long-term effects of slow-cortical poten-
tial neurofeedback (SCP-NF) treatment for children with ADHD in a large multicenter ran-
domized controlled trial, on its relation to aggressive behaviors as a common comorbidity of 
ADHD, and on neuroimaging and psychophysiological subtypes of aggression. We assessed 
clinical efficacy on ADHD and comorbid aggression in comparison to a semi-active control 
group which controlled for unspecific effects. The role of self-regulation and learning of SCPs 
was systematically evaluated. Additionally, we investigated amygdala-specific activity in ag-
gression subtypes in a large multicenter cohort, which might provide a possible putative NF 
target. 
The first two studies assessed 150 children aged 7–9 years diagnosed with ADHD which were 
randomized to 25 sessions of feedback of SCPs (NF) or feedback of coordination of the su-
praspinatus muscles (EMG). The primary outcome was the change in ADHD symptoms rated 
by parents four weeks and six-month after treatment end. Slow-cortical potential neurofeed-
back showed significant superiority over the semi-active control condition with medium ef-
fect sizes four weeks after treatment. This superiority of SCP-NF over the semi-active control 
group became non-significant 6 months after treatment end. However, taking together all as-
sessments, SCP-NF showed a stable improvement with large effect sizes following treatment 
and EMG-BF showed worsening of symptoms one month after treatment, with subsequent 
remission at follow-up, leading to non-significant group differences six months after treat-
ment end. Assessment of self-regulation showed significant ability to self-regulate slow-
cortical potential when direct feedback is given and improvement of self-regulation skills in-
dicate specificity of SCP-NF for selected subscales after training, but not at follow-up. In 
sum, these findings suggest shared specific and unspecific effects contributing to this clinical 
outcome.  
The third study aimed to disentangle aggression-related subtypes at a neural level. In total 177 
participants (n=108 cases with aggression-related disorders and n= 69 typically developing 
peers), aged 8-18 years were assessed across nine sites in Europa during a well-established 
emotional face-matching fMRI task. Additionally, simultaneous skin conductance recordings 
were acquired in a subsample (n=64). Children and adolescents with aggression-related prob-
lems showed higher amygdala activity in response to negative faces compared to typically 
developing peers. Further, we showed distinct amygdala activity for subtypes of aggression. 
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Callous-unemotional traits showed to moderate both central (amygdala) and peripheral (SC) 
responses. These findings increase insights which could be used for personalized diagnostics 
and treatments.  
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